ClinicalTrials.gg
CompletedNCT03000439Updated Jun 3, 2025Results posted

A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA

A Phase 3 interventional study of In open-label phase: treatment with tofacitinib and In double-blind phase: treatment with tofacitinib or placebo in 1:1 ratio in Arthritis Juvenile Idiopathic, sponsored by Pfizer. Completed at 52 sites in 19 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-06-03.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Arthritis, Juvenile by Pfizer — 1 open to participants now, 1 under way, none of them phase 3. Arthritis, Juvenile · Pfizer.

Started
2018
the only one that year
Phase 3
4 of 10
none open now
Registered
9th of 10
by date

Among the 10 studies in Arthritis, Juvenile by Pfizer, this one is the only one that started in 2018, is one of 4 in phase 3, and was the 9th registered.

Arthritis, Juvenile

366 studies on the registry are indexed under Arthritis, Juvenile; 101 are open to participants now.

Browse Arthritis, Juvenile studies →

Open to participants now

1 of the 10 studies in Arthritis, Juvenile by Pfizer is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Arthritis, Juvenile by Pfizer, or all of them as a file.
02

Study summary

A randomized withdrawal study in which responders to open-label treatment with tofacitinib will be randomized in a 1:1 ratio to tofacitinib or placebo in a double-blind phase. In the double-blind phase "time to sJIA flare" will be evaluated as primary endpoint and subjects will be discontinued once they experience sJIA flare. An interim analysis for efficacy and futility will be conducted when at least 20 flares have been observed. If either criterion is met, the study will be stopped. If neither criterion is met, the study will continue until the requisite number of flares are observed as determined by the number of flares included in the interim analysis and a statistical penalty for conducting the interim analysis.

03

Conditions studied

  • Arthritis Juvenile Idiopathic

Browse trials for

Keywords

  • systemic Juvenile Idiopathic Arthritis
  • Xeljanz
  • Tofacitinib
  • sJIA
  • CP-690 550
04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • active sJIA disease according to ILAR criteria before screening and at baseline (Day 1);
  • Treatment with stable doses of methotrexate (MTX) ≤25 mg/week or ≤20 mg/m2/week, whichever is lower, is permitted;
  • Treatment with a stable dose of oral prednisone ≤1 mg/kg/day up to a maximum of 30 mg/day, or equivalent, for at least 1 week before the first study drug dose is permitted.

Exclusion criteria

Exclusion Criteria:

  • Previous juvenile idiopathic arthritis (JIA) treatment with tofacitinib.
  • Current symptoms or findings of myocarditis, endocarditis or more than minimal pericardial effusion associated with systemic juvenile idiopathic arthritis (sJIA). Current symptoms or findings of more than minimal pleuritis with sJIA.
  • Current infection or serious infection within 3 months of study enrollment.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Tofacitinib 5 mg BID

    oral, twice daily, tablet or solution.

    Drug: In open-label phase: treatment with tofacitinib · Drug: In double-blind phase: treatment with tofacitinib or placebo in 1:1 ratio

  • Placebo comparator
    Placebo

    Drug: In double-blind phase: treatment with tofacitinib or placebo in 1:1 ratio

Interventions

  • DrugIn open-label phase: treatment with tofacitinib

    Drug page: Tofacitinib

    Treatment with investigational drug

    Also known as: CP-690,550, Xeljanz

  • DrugIn double-blind phase: treatment with tofacitinib or placebo in 1:1 ratio

    Treatment with investigational drug or placebo

    Also known as: CP-690,550, Xeljanz

06

What researchers measure

Primary outcomes

  1. Time to Systemic Juvenile Idiopathic Arthritis (sJIA) Disease Flare: Double-Blind Phase

    Time to the disease flare=the number of days from randomization to flare in the DB phase and calculated as date of disease flare minus (-) date of randomization plus (+) 1. sJIA Flare=as at least one of the following criteria: Recurrence of fever \>38 degree Celsius (C)/100.4 degree Fahrenheit (F) on 2 or more consecutive days) was considered due to SJIA activity. Worsening of 30 percent (%) or more in three or more of the six variables included: Number of joints with active arthritis and limited range of motion, disease activity, parent child evaluation of overall well-being, functional ability, childhood health assessment questionnaire ( CHAQ disability index), erythrocyte sedimentation rate (ESR) millimeter/ hour (mm/hr), of the JIA core set with no more than one variable of the JIA core set improving by 30% compared to the day of randomization into the withdrawal phase. 95% Confidence Interval (CI) based on Brookmeyer and Crowley Method.

    Time frame: From randomization up to 248 weeks

Secondary outcomes

  1. Probability of Occurrence of sJIA Disease Flare at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52: Double-Blind Phase

    sJIA Flare was defined as at least one of the following criteria: recurrence of fever (\>38° C/100.4 degree F) on 2 or more consecutive days) was considered due to SJIA activity. Worsening of 30% or more in three or more of the six variables: number of joints with active arthritis and limited range of motion, disease activity, parent child evaluation of overall well-being, functional ability (CHAQ Disability Index), ESR. of the JIA core set with no more than one variable of the JIA core set improving by 30% compared to the day of randomization into the withdrawal phase. Probability of occurrence of sJIA disease flare with 95% CI were estimated using Kaplan-Meier method and reported in this outcome measure.

    Time frame: DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

  2. Percentage of Participants Who Achieved Successful Corticosteroid Tapering: at the End of Open-label Phase Part 2

    A successfully tapered participant was considered as the one that completed part 2 of the OL by reaching their target corticosteroid dose and maintained an adapted JIA American College of Rheumatology (ACR) 30 response for four weeks on this dose. The target CS dose at the end of part 2 included less than equal to (\<=) 0.5 milligram/kilogram/day (mg/kg/day) up to a maximum dose of 15 milligram/ day (mg/day) oral prednisone (or equivalent) for CS\>0.8 mg/kg/day oral prednisone; reduction to \<=0.3 mg/kg/day up to a maximum of 12 mg/day oral prednisone (or equivalent) for CS \<=0.8 mg/kg/day to greater than equal to (\>=) 0.5 mg/kg/day oral prednisone (or equivalent) and \<=0.2 mg/kg/day up to a maximum dose of 10 mg/day oral prednisone (or equivalent) for CS \<0.5 mg/kg/day-CS˃0.2 mg/kg/day oral prednisone (or equivalent). 95% CI was based on normal approximation.

    Time frame: From end of OL Part 1 to up to 24 weeks in OL Part 2

  3. Percentage of Participants Who Achieved Corticosteroid Dose of <= 0.2 mg/kg/Day or 10 mg/Day: at the End of Open-label Phase Part 2

    95% CI was based on normal approximation.

    Time frame: From end of OL Part 1 to up to 24 weeks in OL Part 2

  4. Percentage of Participants With Adapted JIA ACR 30/50/70/90/100 Response at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase

    Adapted JIA ACR 30,50,70,90,100 response=absence of fever due to sJIA in preceding 7 days along with improvement of \>=30,50,70,90,100%, respectively in at least 3 out of 6 JIA core set variables with no more than 1 JIA core set variable worsening by \>=30%.Variables included: number of joints with active arthritis(any joint with swelling, or absence of swelling, limitation of motion accompanied by either pain on motion or tenderness);number of joints with limited range of motion; physician global evaluation of disease activity on VAS from 0=no disease activity to 10=very severe disease activity, higher scores:greater disease activity; parent/legal guardian/child evaluation of overall well-being on VAS from 0=very well to 10mm=very poor, higher scores: worsen condition; functional ability (Disability Index ranged from 0=no or minimal physical dysfunction, 3=very severe physical dysfunction, higher scores:more physical dysfunction;ESR (mm/hr).Missing response was imputed as non-response.

    Time frame: DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

  5. Percentage of Participants With Adapted JIA American College of Rheumatology (ACR) 30/50/70/90/100 Response at Part 1 Day 7, Weeks 2, 4, 8, 12, and 16: Open-Label Phase Part 1

    Adapted JIA ACR 30,50,70,90,100 response=absence of fever due to sJIA in preceding 7 days along with improvement of \>=30,50,70,90,100%, respectively in at least 3 out of 6 JIA core set variables with no more than 1 JIA core set variable worsening by \>=30%.Variables included: number of joints with active arthritis(any joint with swelling, or absence of swelling, limitation of motion accompanied by either pain on motion or tenderness);number of joints with limited range of motion; physician global evaluation of disease activity on VAS from 0=no disease activity to 10=very severe disease activity, higher scores: greater disease activity; parent/legal guardian/child evaluation of overall well-being on VAS from 0=very well to 10mm=very poor, higher scores: worsen condition; functional ability (Disability Index ranged from 0=no or minimal physical dysfunction, 3=very severe physical dysfunction, higher scores: more physical dysfunction; ESR (mm/hr).

    Time frame: Part 1 Day 7, Part 1 Weeks 2, 4, 8, 12, and 16

  6. Percentage of Participants With Adapted JIA ACR 30/50/70/90/100 Response at Part 2 Weeks 4, 8, 12, 16, 20 and 24: Open-label Phase Part 2

    Adapted JIA ACR 30,50,70,90,100 response=absence of fever due to sJIA in preceding 7 days along with improvement of \>=30,50,70,90,100%, respectively in at least 3 out of 6 JIA core set variables with no more than 1 JIA core set variable worsening by \>=30%.Variables included: number of joints with active arthritis(any joint with swelling, or absence of swelling, limitation of motion accompanied by either pain on motion or tenderness);number of joints with limited range of motion; physician global evaluation of disease activity on VAS from 0=no disease activity to 10=very severe disease activity, higher scores: greater disease activity; parent/legal guardian/child evaluation of overall well-being on VAS from 0=very well to 10mm=very poor, higher scores: worsen condition; functional ability (Disability Index ranged from 0=no or minimal physical dysfunction, 3=very severe physical dysfunction, higher scores: more physical dysfunction; ESR (mm/hr).

    Time frame: Part 2 Weeks 4, 8, 12, 16, 20 and 24

  7. Percentage of Participants With Fever Attributed to sJIA at Part 1 Days 3, 7 and 14: Open-Label Phase Part 1

    Fever was defined as an oral temperature of ˃38 degree Celsius/100.4 degree Fahrenheit. 95% CI was based on normal approximation.

    Time frame: Part 1 Days 3, 7 and 14

  8. Percentage of Participants With C-Reactive Protein (CRP) <= 10 mg/L at Baseline, Part 1 Days 3, 7, Weeks 2, 4, 8, 12, 16: Open-Label Phase Part 1

    Percentage of participants with CRP \<= 10 milligrams per liter (mg/L) along with 95% CI based on normal approximation is reported in this outcome.

    Time frame: Baseline (last value collected prior to Day 1 of study treatment), Part 1 Days 3, 7, Part 1 Weeks 2, 4, 8, 12, 16

  9. Percentage of Participants With C-Reactive Protein (CRP) <= 10 mg/L at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2

    Percentage of participants with CRP \<= 10 mg/L along with 95% CI based on normal approximation is reported in this outcome.

    Time frame: Part 2 Weeks 4, 8, 12, 16, 20, 24

  10. Percentage of Participants With Absence of Fever Due to sJIA at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-label Phase Part 1

    Percentage of participants with absence of fever along with 95% CI based on normal approximation is reported in this outcome.

    Time frame: Part 1 Day 7, Part 1 Weeks 2, 4, 8, 12, 16

  11. Percentage of Participants With Absence of Fever Due to sJIA at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2

    Percentage of participants with absence of fever along with 95% CI based on normal approximation is reported in this outcome.

    Time frame: Part 2 Weeks 4, 8, 12, 16, 20 and 24

  12. Percentage of Participants With Absence of Fever Due to sJIA at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52: Double Blind Phase

    Percentage of participants with absence of fever due sJIA is reported in this outcome. Missing response was imputed as non-response.

    Time frame: DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

  13. Time to First Adapted JIA ACR 30 Response: Open-label Phase Part 1

    Time to the first adapted JIA ACR 30 response was measured in number of days since Day 1 (day of adapted JIA ACR 30 response - Day 1 + 1) in the OL Phase Part 1. Participants that did not achieve an adapted JIA ACR30 response defined as absence of fever due to sJIA \[temperature =\<38 degree Celsius/100.4 degree F in the preceding 7 days along with an improvement of at least 30% from baseline (Day 1 of study drug before first tofacitinib administration) in at least 3 of the 6 JIA core components, with worsening of \>=30 in no more than 1 of the remaining components, which in Part 1 (withdrew from the study) were censored at their last available response assessment in Part 1. 95% CI was based on the Brookmeyer and Crowley Method.

    Time frame: From Day 1 up to 16 weeks

  14. Change From Open Label Baseline in Juvenile Arthritis Disease Activity Score (JADAS-27) Erythrocyte Sedimentation Rate (ESR) at Part 1 Day 7, Part 1 Weeks 2, 4, 8, 12 and 16: Open-Label Phase Part 1

    JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 ESR score was determined based on four components: Physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ) assessed on a VAS of 0 \[very well\] to 10 \[very poor\], ESR (value normalized to 0 to 10 scale) and number of joints with active disease (27 joint assessment ranging from 0 to 27). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.

    Time frame: Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 1 Day 7, Part 1 Weeks 2, 4, 8, 12 and 16

  15. Change From Open-Label Baseline in JADAS-27 CRP at Part 1 Day 7, Part 1 Weeks 2, 4, 8, 12 and 16: Open-Label Phase Part 1

    JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score was determined based on four components: physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), CRP (value normalized to 0 to 10 scale) and number of joints with active disease (27 joint assessment ranging from 0 to 27). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.

    Time frame: Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 1 Day 7, Part 1 Weeks 2, 4, 8, 12 and 16

  16. Change From Open-Label Baseline in JADAS-27 ESR at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2

    JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 ESR score was determined based on four components: physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), ESR (value normalized to 0 to 10 scale) and number of joints with active disease (27 joint assessment ranging from 0 to 27). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.

    Time frame: Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 2 Weeks 4, 8, 12, 16, 20 and 24

  17. Change From Open-Label Baseline in JADAS-27 CRP at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2

    JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score was determined based on four components: physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), CRP (value normalized to 0 to 10 scale) and number of joints with active disease (27 joint assessment ranging from 0 to 27). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.

    Time frame: Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 2 Weeks 4, 8, 12, 16, 20 and 24

  18. Change From Double-Blind Baseline in JADAS-27 ESR at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase

    JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 ESR score was determined based on four components: Physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ) (assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), ESR (value normalized to 0 to 10 scale) and number of joints with active disease (27 joint assessment ranging from 0 to 27). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.

    Time frame: DB Baseline (at randomization on Day 1 in DB phase), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

  19. Change From Double-Blind Baseline in JADAS-27 CRP at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase

    JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score was determined based on four components: Physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), CRP (value normalized to 0 to 10 scale) and number of joints with active disease (27 joint assessment ranging from 0 to 27). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.

    Time frame: DB Baseline (at randomization on Day 1 in DB phase), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

  20. Change From Open-Label Baseline in Number of Joints With Active Arthritis at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-Label Phase Part 1

    The ACR defined a joint with active arthritis as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by pain on motion, or tenderness.

    Time frame: Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 1 Day 7, Part 1 Weeks 2, 4, 8, 12 and 16

  21. Change From Open-Label Baseline in Number of Joints With Active Arthritis at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2

    The ACR defined a joint with active arthritis as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by pain on motion, or tenderness.

    Time frame: Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 2 Weeks 4, 8, 12, 16, 20, 24

  22. Change From Open-Label Baseline in Number of Joints With Limited Range of Motion at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-Label Phase Part 1

    Limitation of motion were assessed in the following joints: Temporomandibular, shoulder, elbow, wrist, metacarpophalangeal (MCP I-V), proximal interphalangeal (PIP I-V), distal interphalangeal (II-V), hip, knee, ankle, subtalar joints, intertarsal joints, metatarsophalangeal (MTP I-V), toe interphalangeal (I-V), cervical spine, thoracic spine, lumbar spine.

    Time frame: Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 1 Day 7, Weeks 2, 4, 8, 12, 16

  23. Change From Open-Label Baseline in Number of Joints With Limited Range of Motion at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2

    Limitation of motion were assessed in the following joints: Temporomandibular, shoulder, elbow, wrist, metacarpophalangeal (MCP I-V), proximal interphalangeal (PIP I-V), distal interphalangeal (II-V), hip, knee, ankle, subtalar joints, intertarsal joints, metatarsophalangeal (MTP I-V), Toe interphalangeal (I-V), cervical spine, thoracic spine, lumbar spine.

    Time frame: Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 2 Weeks 4, 8, 12, 16, 20, 24

  24. Change From Open-Label Baseline in Physician Global Evaluation of Disease Activity at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-label Phase Part 1

    Physician global evaluation of disease activity was assessed on a 21-numbered circle VAS ranging from 0 to 10, where 0= no disease activity and 10= maximum disease activity. Where higher scores indicated more disease activity.

    Time frame: Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 1 Day 7, Weeks 2, 4, 8, 12, 16

  25. Change From Open-Label Baseline in Physician Global Evaluation of Disease Activity at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2

    Physician global evaluation of disease activity was assessed on a 21-numbered circle VAS ranging from 0 to 10, where 0= no disease activity and 10= maximum disease activity. Where higher scores indicated more disease activity.

    Time frame: Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 2 Weeks 4, 8, 12, 16, 20, 24

  26. Change From Open-Label Baseline in ESR at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-Label Phase Part 1

    ESR was determined using an ESR testing kit.

    Time frame: Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 1 Day 7, Weeks 2, 4, 8, 12, 16

  27. Change From Open-Label Baseline in ESR at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2

    ESR was determined using an ESR testing kit.

    Time frame: Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 2 Weeks 4, 8, 12, 16, 20, 24

  28. Change From Open-Label Baseline in CHAQ- Parental Evaluation of Overall Well-being at Part 1 Days 3, 7, Part 1 Weeks 2, 4, 8, 12, 16: Open-Label Phase Part 1

    The CHAQ, derived from the adult health assessment questionnaire, comprised of two indices disability and discomfort, and parent global assessment of overall well-being. For assessment of overall well-being, the parent/legal guardian/participant were required to rate the overall well-being by entering a number from 0 to 10 (in 0.5 increments), on a 21-circle VAS where '0= very well and 10=very poorly. Where higher scores indicated worse condition.

    Time frame: Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 1 Days 3,7, Part 1 Weeks 2, 4, 8, 12, 16

  29. Change From Open-Label Baseline in CHAQ - Parental Evaluation of Overall Well-being at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2

    The CHAQ, derived from the adult health assessment questionnaire, comprised of two indices disability and discomfort, and parent global assessment of overall well-being. For assessment of overall well-being, the parent/legal guardian/participant were required to rate the overall well-being by entering a number from 0 to 10 (in 0.5 increments), on a 21-circle VAS where '0=Very Well and 10=Very Poorly. Where higher scores indicated worse condition.

    Time frame: Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 2 Weeks 4, 8, 12, 16, 20, 24

  30. Change From Open-Label Baseline in CHAQ - Disability Index at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-Label Phase Part 1

    CHAQ, derived from the adult health assessment questionnaire, comprised of two indices disability and discomfort, and parent global assessment of overall Well-being. CHAQ disability index consisted of 30 items in 8 areas: 1. dressing and grooming, 2. arising, 3. eating, 4. walking, 5. hygiene, 6. reach, 7. grip, and 8. activities distributed. Each item was rated on a 4-point scale, scored from 0 (no difficulty) to 3 (unable to do). The eight areas of the CHAQ were averaged to calculate the total disability index score which ranged from 0 (no or minimal physical dysfunction) to 3 (very severe physical dysfunction), higher scores indicated more disability. A participant must have score for at least six of the eight areas, otherwise a CHAQ-DI score was not valid.

    Time frame: Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 1 Day 7, Weeks 2, 4, 8, 12, 16

  31. Change From Open-Label Baseline in CHAQ-Disability Index at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2

    CHAQ, derived from the adult health assessment questionnaire, comprised of two indices disability and discomfort, and parent global assessment of overall well-being. CHAQ disability index consisted of 30 items in 8 areas, 1. dressing and grooming, 2. arising, 3. eating, 4. walking, 5. hygiene, 6. reach, 7. grip, and 8. activities distributed. Each item was rated on a 4-point scale, scored from 0 (no difficulty) to-3 (unable to do). The eight areas of the CHAQ were averaged to calculate the total disability index score which ranged from 0 (no or minimal physical dysfunction) to 3 (very severe physical dysfunction), higher scores indicated more disability. A participant must have score for at least six of the eight areas, otherwise a CHAQ-DI score was not valid.

    Time frame: Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 2 Weeks 4, 8, 12, 16, 20, 24

  32. Change From Open-Label Baseline in Number of Joints With Active Arthritis at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase

    The ACR defined a joint with active arthritis as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by pain on motion, or tenderness.

    Time frame: OL Baseline (last value collected prior to Day 1 of tofacitinib administration in OL phase), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

  33. Change From Double-Blind Baseline in Number of Joints With Active Arthritis at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase

    The ACR defined a joint with active arthritis as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by pain on motion, or tenderness.

    Time frame: DB Baseline (randomization), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

  34. Change From Open-Label Baseline in CHAQ-Disability Index at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase

    The parents were asked to provide responses to questions designed to assessed function in 8 distributed, among a total of 30 items. Each question was rated on a four-point scale, scored from 0-3. The question with the highest score determined the score for the functional area. If aids or devices were used or assistance was required, the minimum score for that was 2. Each question was rated 0 for no difficulty, 1 for some difficulties, 2 for much difficulties, and 3 for unable to do. The 8 areas of the CHAQ were averaged to calculated disability index which was ranges from 0 (no or minimal physical dysfunction) to 3 (very severe physical dysfunction). A participant must have score for at least 6 of the 8 categories, otherwise a CHAQ-DI score was not valid.

    Time frame: OL Baseline (last value collected prior to Day 1 of tofacitinib administration in OL phase), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

  35. Change From Double Blind Baseline in CHAQ-Disability Index at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase

    The parents were asked to provide responses to questions designed to assessed function in 8 distributed, among a total of 30 items. Each question was rated on a four-point scale, scored from 0-3. The question with the highest score determined the score for the functional area. If aids or devices were used or assistance was required, the minimum score for that was 2. Each question was rated 0 for no difficulty, 1 for some difficulties, 2 for much difficulties, and 3 for unable to do. The 8 areas of the CHAQ were averaged to calculated disability index which was ranges from 0 (no or minimal physical dysfunction) to 3 (very severe physical dysfunction). A participant must have score for at least 6 of the 8 categories, otherwise a CHAQ-DI score was not valid.

    Time frame: DB Baseline (randomization), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

  36. Change From Open-Label Baseline in Number of Joints With Limited Range of Motion at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase

    Limitation of motion were assessed in the following joints: Temporomandibular, shoulder, elbow, wrist, metacarpophalangeal (MCP I-V), proximal interphalangeal (PIP I-V), distal interphalangeal (II-V), hip, knee, ankle, subtalar joints, intertarsal joints, metatarsophalangeal (MTP I-V), toe interphalangeal (I-V), cervical spine, thoracic spine, lumbar spine.

    Time frame: OL baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

  37. Change From Double-Blind Baseline in Number of Joints With Limited Range of Motion at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase

    Limitation of motion were assessed in the following joints: Temporomandibular, shoulder, elbow, wrist, metacarpophalangeal (MCP I-V), proximal interphalangeal (PIP I-V), distal interphalangeal (II-V), hip, knee, ankle, subtalar joints, intertarsal joints, metatarsophalangeal (MTP I-V), toe interphalangeal (I-V), cervical spine, thoracic spine, lumbar spine.

    Time frame: DB Baseline (values at randomization), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

  38. Change From Open-Label Baseline in Physician Global Evaluation of Disease Activity at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase

    Physician global evaluation of disease activity was assessed on a 21-numbered circle VAS ranging from 0 to 10, where 0= no disease activity and 10=maximum disease activity, where higher scores indicated more disease activity.

    Time frame: OL label Baseline (last value collected prior to Day 1 of tofacitinib administration in OL phase), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

  39. Change From Double-Blind Baseline in Physician Global Evaluation of Disease Activity at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase

    Physician global evaluation of disease activity was assessed on a 21-numbered circle VAS ranging from 0 to 10, where 0= no disease activity and 10=maximum disease activity, where higher scores indicated more disease activity.

    Time frame: DB label Baseline (last value collected prior to Day 1 of tofacitinib administration in OL phase), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

  40. Change From Open-Label Baseline in ESR at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase

    ESR was determined using an ESR testing kit.

    Time frame: OL Baseline (last value collected prior to Day 1 of tofacitinib administration in OL phase), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

  41. Change From Double-Blind Baseline in ESR at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase

    ESR was determined using an ESR testing kit.

    Time frame: DB Baseline (values at randomization), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

  42. Change From Open-Label Baseline in CHAQ -Parental Evaluation of Overall Well-being at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase

    The CHAQ, derived from the adult health assessment questionnaire, comprised of two indices disability and discomfort, and parent global assessment of overall well-being. For assessment of overall well-being, the parent/legal guardian/participant were required to rate the overall well-being by entering a number from 0 to 10 (in 0.5 increments), on a 21-circle VAS where '0'= very well' and '10= very poorly, where higher scores indicated worse condition.

    Time frame: OL label Baseline (last value collected prior to Day 1 of tofacitinib administration in OL phase), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

  43. Change From Double-Blind Baseline in CHAQ -Parental Evaluation of Overall Well-being at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase

    The CHAQ, derived from the adult health assessment questionnaire, comprised of two indices disability and discomfort, and parent global assessment of overall well-being. For assessment of overall well-being, the parent/legal guardian/participant were required to rate the overall well-being by entering a number from 0 to 10 (in 0.5 increments), on a 21-circle VAS where '0'= very well' and '10=very poorly.

    Time frame: DB Baseline (value at randomization), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

  44. Change From Open-Label Baseline in Child Health Questionnaire (CHQ) Responses at End of Open-Label Phase Part 1

    The CHQ is a validated general pediatric quality of life instrument. The CHQ assessed for 14 physical and psychosocial domains: general health perceptions (global health perception), physical functioning, role/social physical functioning, bodily pain, role/social emotional functioning, role/social behavioral functioning, parent/legal guardian/adult caregiver impact-time, parent/legal guardian/adult caregiver impact-emotional, self-esteem, mental health, behavior, family activities, family cohesion, and change in health. The response options for the CHQ are ordinal scales that vary by the item. Each item consisted of 4-6 response options. The CHQ score was determined based on the parent/legal guardian/adult caregiver's questionnaire responses. Range on subscales and the overall scale is 0 to 100, where 0 is the worst possible health state and 100 the best possible health state.

    Time frame: OL Baseline up to 16 weeks

  45. Change From Open-Label Baseline in CHQ Responses at End of Open-Label Phase Part 2

    The CHQ is a validated general pediatric quality of life instrument. The CHQ assessed for 14 physical and psychosocial domains: general health perceptions (global health perception), physical functioning, role/social physical functioning, bodily pain, role/social emotional functioning, role/social behavioral functioning, parent/legal guardian/adult caregiver impact-time, parent/legal guardian/adult caregiver impact-emotional, self-esteem, mental health, behavior, family activities, family cohesion, and change in health. The response options for the CHQ are ordinal scales that vary by the item. Each item consisted of 4-6 response options. The CHQ score was determined based on the parent/legal guardian/adult caregiver's questionnaire responses. Range on subscales and the overall scale is 0 to 100, where 0 is the worst possible health state and 100 the best possible health state.

    Time frame: Baseline (last value collected prior to Day 1 of tofacitinib administration in OL phase) up to 24 weeks

  46. Change From Double-Blind Baseline in CHQ Responses at DB Weeks 24, 48: Double-Blind Phase

    The CHQ is a validated general pediatric quality of life instrument. The CHQ assessed for 14 physical and psychosocial domains: general health perceptions (global health perception), physical functioning, role/social physical functioning, bodily pain, role/social emotional functioning, role/social behavioral functioning, parent/legal guardian/adult caregiver impact-time, parent/legal guardian/adult caregiver impact-emotional, self-esteem, mental health, behavior, family activities, family cohesion, and change in health. The response options for the CHQ are ordinal scales that vary by the item. Each item consisted of 4-6 response options. The CHQ score was determined based on the parent/legal guardian/adult caregiver's questionnaire responses. Range on subscales and the overall scale is 0 to 100, where 0 is the worst possible health state and 100 the best possible health state.

    Time frame: DB Baseline (values at randomization), DB Weeks 24, 48

  47. Change From Open-Label Baseline in CHAQ-Discomfort Index at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-Label Phase Part 1

    For the assessment of discomfort, the parent/legal guardian or adult caregiver who interacted daily with the participant were required to rate the overall pain the participant had due to illness by entering a number from 0 to 10 (in 0.5 increments), with '0' as 'no pain' and '10' as 'very severe pain' on a 21-circle VAS, where higher scores indicated more severe pain.

    Time frame: Baseline (last value collected prior to Day 1 of tofacitinib administration in OL phase) Part 1 Day 7, Weeks 2, 4, 8, 12, 16

  48. Change From Open-label Baseline in CHAQ-Discomfort Index at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2

    For the assessment of discomfort, the parent/legal guardian or adult caregiver who interacted daily with the participant were required to rate the overall pain the participant had due to illness by entering a number from 0 to 10 (in 0.5 increments), with '0' as 'no pain' and '10' as 'very severe pain' on a 21-circle VAS, where higher scores indicated more pain.

    Time frame: Baseline (last value collected prior to Day 1 of tofacitinib administration in OL phase) Part 2 Weeks 4, 8, 12, 16, 20, 24

  49. Change From Double-Blind Baseline in CHAQ-Discomfort Index at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase

    For the assessment of discomfort, the parent/legal guardian or adult caregiver who interacted daily with the participant were required to rate the overall pain the participant had due to illness by entering a number from 0 to 10 (in 0.5 increments), with '0' as 'no pain' and '10' as 'very severe pain' on a 21-circle VAS, where higher scores indicated more severe pain.

    Time frame: DB Baseline (value at randomization), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

  50. Percentage of Participants With Minimum Disease Activity Calculated From JADAS-27 CRP Score at Part 1 Day 7, Weeks 2, 4, 8, 12 and 16: Open-Label Phase Part 1

    JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score were determined based on four components: Physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 (very well) to 10 (very poor), CRP (value normalized to 0 to 10 scale, where higher scores indicated more inflammation) and number of joints with active disease (27 joint assessment ranging from 0 to 27, where higher scores indicated more disease activity). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57, where higher scores indicated more disease activity. For participants with polyarthritis (\>4 active joints) minimal disease activity was defined as a JADAS-27 CRP score of: \<= 3.8. For participants with oligoarthritis (\<= 4 active joints) minimal disease activity was defined as a JADAS-27 CRP score of \<=2.

    Time frame: Part 1 Day 7, Part 1 Weeks 2, 4, 8, 12 and 16

  51. Percentage of Participants With Minimum Disease Activity Calculated From JADAS-27 ESR Score at Part 1 Day 7, Weeks 2, 4, 8, 12 and 16: Open-label Phase Part 1

    JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 ESR score were determined based on four components: Physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 (very well) to 10 (very poor), ESR (value normalized to 0 to 10 scale, where higher scores indicated more inflammation) and number of joints with active disease (27 joint assessment ranging from 0 to 27, where higher scores indicated more disease activity). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57, where higher scores indicated more disease activity. For participants with polyarthritis (\>4 active joints) minimal disease activity was defined as a JADAS-27 ESR score of: \<= 3.8. For participants with oligoarthritis (\<= 4 active joints) minimal disease activity was defined as a JADAS-27 ESR score of \<=2.

    Time frame: Part 1 Day 7, Weeks 2, 4, 8, 12 and 16

  52. Percentage of Participants With Minimum Disease Activity Calculated From JADAS-27 CRP Score at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2

    JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score were determined based on four components: Physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 (very well) to 10 (very poor), CRP (value normalized to 0 to 10 scale, where higher scores indicated more inflammation) and number of joints with active disease (27 joint assessment ranging from 0 to 27, where higher scores indicated more disease activity). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57, where higher scores indicated more disease activity. For participants with polyarthritis (\>4 active joints) minimal disease activity was defined as a JADAS-27 CRP score of: \<= 3.8. For participants with oligoarthritis (\<= 4 active joints) minimal disease activity was defined as a JADAS-27 CRP score of \<=2.

    Time frame: Part 2 Weeks 4, 8, 12, 16, 20, 24

  53. Percentage of Participants With Minimum Disease Activity Calculated From JADAS-27 ESR Score at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2

    JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 ESR score were determined based on four components: Physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 (very well) to 10 (very poor), ESR (value normalized to 0 to 10 scale, where higher scores indicated more inflammation) and number of joints with active disease (27 joint assessment ranging from 0 to 27, where higher scores indicated more disease activity). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57, where higher scores indicated more disease activity. For participants with polyarthritis (\>4 active joints) minimal disease activity was defined as a JADAS-27 ESR score of: \<= 3.8. For participants with oligoarthritis (\<= 4 active joints) minimal disease activity was defined as a JADAS-27 ESR score of \<=2.

    Time frame: Part 2 Weeks 4, 8, 12, 16, 20, 24

  54. Percentage of Participants With Inactive Disease Status Calculated From JADAS-27 CRP Score at Part 1 Day 7, Weeks 2, 4, 8, 12 and 16: Open-label Phase Part 1

    JADAS-27 is a validated composite disease activity measure for JIA. Score were determined based on four components:Physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 (very well) to 10 (very poor), CRP (value normalized to 0 to 10 scale, where higher scores:more inflammation) and number of joints with active disease (27 joint assessment ranging from 0 to 27,where higher scores:more disease activity). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57,where higher scores:more disease activity.Inactive disease activity based on JADAS-27 CRP score was defined as: For participants with polyarthritis (\>4 active joints) inactive disease activity was defined as a JADAS-27 CRP score of:\<=1.For participants with oligoarthritis (\<=4 active joints) inactive disease activity was defined as a JADAS-27 CRP score of \<=1.

    Time frame: Part 1 Day 7, Weeks 2, 4, 8, 12 and 16

  55. Percentage of Participants With Inactive Disease Status Calculated From JADAS-27 ESR Score at Part 1 Day 7, Weeks 2, 4, 8, 12 and 16: Open-Label Phase Part 1

    JADAS-27 is a validated composite disease activity measure for JIA. Score were determined based on four components:physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity);parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 (very well) to 10 (very poor), ESR (value normalized to 0 to 10 scale, where higher scores:more inflammation and number of joints with active disease (27 joint assessment ranging from 0 to 27, where higher scores:more disease activity). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57, where higher scores:more disease activity. Inactive Disease activity based on JADAS-27 ESR score was defined as for participants with polyarthritis(\>4 active joints) inactive disease activity was defined as a JADAS-27 ESR score of:\<=1. For participants with oligoarthritis (\<=4 active joints) inactive disease activity was defined as a JADAS-27 ESR score of \<=1.

    Time frame: Part 1 Day 7, Weeks 2, 4, 8, 12 and 16

  56. Percentage of Participants With Inactive Disease Status Calculated From JADAS-27 CRP Score at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2

    JADAS-27 is a validated composite disease activity measure for JIA.Score were determined based on four components:physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity);parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 (very well) to 10 (very poor), CRP (value normalized to 0 to 10 scale, where higher scores: more inflammation) and number of joints with active disease (27 joint assessment ranging from 0 to 27,where higher scores:more disease activity). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57,where higher scores: more disease activity.Inactive disease activity based on JADAS-27 CRP score was defined as: For participants with polyarthritis (\>4 active joints) inactive disease activity was defined as a JADAS-27 CRP score of:\<=1.For participants with oligoarthritis (\<=4 active joints) inactive disease activity was defined as a JADAS-27 CRP score of \<=1.

    Time frame: Part 2 Weeks 4, 8, 12, 16, 20, 24

  57. Percentage of Participants With Inactive Disease Status Calculated From JADAS-27 ESR Score at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2

    JADAS-27 is a validated composite disease activity measure for JIA. Score were determined based on four components:physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity);parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 (very well) to 10 (very poor), ESR (value normalized to 0 to 10 scale, where higher scores:more inflammation and number of joints with active disease (27 joint assessment ranging from 0 to 27, where higher scores:more disease activity). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57, where higher scores:more disease activity. Inactive Disease activity based on JADAS-27 ESR score was defined as for participants with polyarthritis(\>4 active joints) inactive disease activity was defined as a JADAS-27 ESR score of:\<=1. For participants with oligoarthritis (\<=4 active joints) inactive disease activity was defined as a JADAS-27 ESR score of \<=1.

    Time frame: Part 2 Weeks 4, 8, 12, 16, 20, 24

  58. Percentage of Participants With Minimum Disease Activity Calculated From JADAS-27 CRP Score at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase

    JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score were determined based on four components: Physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 (very well) to 10 (very poor), CRP (value normalized to 0 to 10 scale, where higher scores indicated more inflammation) and number of joints with active disease (27 joint assessment ranging from 0 to 27, where higher scores indicated more disease activity). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57, where higher scores indicated more disease activity. For participants with polyarthritis (\>4 active joints) minimal disease activity was defined as a JADAS-27 CRP score of: \<= 3.8. For participants with oligoarthritis (\<= 4 active joints) minimal disease activity was defined as a JADAS-27 CRP score of \<=2.

    Time frame: DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52

  59. Percentage of Participants With Minimum Disease Activity Calculated From JADAS-27 ESR Score at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase

    JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 ESR score were determined based on four components: Physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 (very well) to 10 (very poor), ESR (value normalized to 0 to 10 scale, where higher scores indicated more inflammation) and number of joints with active disease (27 joint assessment ranging from 0 to 27, where higher scores indicated more disease activity). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57, where higher scores indicated more disease activity. For participants with polyarthritis (\>4 active joints) minimal disease activity was defined as a JADAS-27 ESR score of: \<= 3.8. For participants with oligoarthritis (\<= 4 active joints) minimal disease activity was defined as a JADAS-27 ESR score of \<=2.

    Time frame: DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52

  60. Percentage of Participants With Inactive Disease Status Calculated From JADAS-27 CRP Score at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase

    JADAS-27 is a validated composite disease activity measure for JIA.Score were determined based on four components:physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 (very well) to 10 (very poor),CRP (value normalized to 0 to 10 scale, where higher scores:more inflammation) and number of joints with active disease (27 joint assessment ranging from 0 to 27, where higher scores:more disease activity).The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57, where higher scores:more disease activity. Inactive disease activity based on JADAS-27 CRP score was defined as: For participants with polyarthritis (\>4 active joints) inactive disease activity was defined as a JADAS-27 CRP score of:\<=1.For participants with oligoarthritis (\<=4 active joints) inactive disease activity was defined as a JADAS-27 CRP score of \<=1.

    Time frame: DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52

  61. Percentage of Participants With Inactive Disease Status Calculated From JADAS-27 ESR Score at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase

    JADAS-27 is a validated composite disease activity measure for JIA. Score were determined based on four components:physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity);parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 (very well) to 10 (very poor), ESR (value normalized to 0 to 10 scale, where higher scores:more inflammation and number of joints with active disease (27 joint assessment ranging from 0 to 27, where higher scores:more disease activity). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57, where higher scores:more disease activity. Inactive Disease activity based on JADAS-27 ESR score was defined as for participants with polyarthritis(\>4 active joints) inactive disease activity was defined as a JADAS-27 ESR score of:\<=1. For participants with oligoarthritis (\<=4 active joints) inactive disease activity was defined as a JADAS-27 ESR score of \<=1.

    Time frame: DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52

  62. Percentage of Participants With JIA ACR Inactive Disease Status at Part 1 Days 3, 7, Weeks 2, 4, 8, 12, 16: Open-Label Phase Part 1

    The ACR clinical inactive disease was defined as follows: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to sJIA; no active uveitis; normal ESR (within normal limits of the method used where tested) or, if elevated, not attributable to JIA; physician global assessment of disease activity score of 'best possible' on the 21-numbered circle VAS scale used (VAS from 0 to 10), higher scores indicated more disease activity; duration of morning stiffness of \<=15 minutes. 95% CI was based on normal approximation.

    Time frame: Baseline (last value collected prior to Day 1 of tofacitinib administration in OL phase) Part 1 Days 3, 7, Weeks 2, 4, 8, 12, 16

  63. Percentage of Participants With JIA ACR Inactive Disease Status at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2

    The ACR clinical inactive disease was defined as follows: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to sJIA; no active uveitis; normal ESR (within normal limits of the method used where tested) or, if elevated, not attributable to JIA; physician global assessment of disease activity score of 'best possible' on the 21-numbered circle VAS scale used (VAS from 0 to 10), higher scores indicated more disease activity; duration of morning stiffness of \<=15 minutes. 95% CI was based on normal approximation. 95% CI was based on normal approximation.

    Time frame: Part 2 Weeks 4, 8, 12, 16, 20, 24

  64. Percentage of Participants With JIA ACR Inactive Disease Status at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase

    The ACR clinical inactive disease was defined as follows: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to sJIA; no active uveitis; normal ESR (within normal limits of the method used where tested) or, if elevated, not attributable to JIA; physician global assessment of disease activity score of 'best possible' on the 21-numbered circle VAS scale used (VAS from 0 to 10), higher scores indicated more disease activity; duration of morning stiffness of \<=15 minutes. 95% CI was based on normal approximation. 95% CI was based on normal approximation.

    Time frame: DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

07

Results

Posted Jun 3, 2025

Participant flow

Participants who were diagnosed with Systemic Juvenile Idiopathic Arthritis (sJIA) with active systemic features were enrolled.

Open Label Part 1
Participant flow — Open Label Part 1
MilestoneTofacitinib 5mg BID Open-Label (OL) Part 1Tofacitinib 5mg BID OL Part 2Tofacitinib 5mg BID DBPlacebo DB
Started100000
Completed76000
Not completed24000
Withdrew: Adverse event6000
Withdrew: Other2000
Withdrew: Insufficient clinical response16000
Open Label Part 2
Participant flow — Open Label Part 2
MilestoneTofacitinib 5mg BID Open-Label (OL) Part 1Tofacitinib 5mg BID OL Part 2Tofacitinib 5mg BID DBPlacebo DB
Started05400
Completed03700
Not completed01700
Withdrew: Other0500
Withdrew: Insufficient clinical response01200
Double Blind Phase
Participant flow — Double Blind Phase
MilestoneTofacitinib 5mg BID Open-Label (OL) Part 1Tofacitinib 5mg BID OL Part 2Tofacitinib 5mg BID DBPlacebo DB
Started002831
Completed001417
Not completed001414
Withdrew: Adverse event0021
Withdrew: Withdrawal by parent/guardian0020
Withdrew: Other001011
Withdrew: Insufficient clinical response0002

Outcome measures

PrimaryTime to Systemic Juvenile Idiopathic Arthritis (sJIA) Disease Flare: Double-Blind Phase

Time to the disease flare=the number of days from randomization to flare in the DB phase and calculated as date of disease flare minus (-) date of randomization plus (+) 1. sJIA Flare=as at least one of the following criteria: Recurrence of fever \>38 degree Celsius (C)/100.4 degree Fahrenheit (F) on 2 or more consecutive days) was considered due to SJIA activity. Worsening of 30 percent (%) or more in three or more of the six variables included: Number of joints with active arthritis and limited range of motion, disease activity, parent child evaluation of overall well-being, functional ability, childhood health assessment questionnaire ( CHAQ disability index), erythrocyte sedimentation rate (ESR) millimeter/ hour (mm/hr), of the JIA core set with no more than one variable of the JIA core set improving by 30% compared to the day of randomization into the withdrawal phase. 95% Confidence Interval (CI) based on Brookmeyer and Crowley Method.

Time frame:
From randomization up to 248 weeks
Reported as:
Median · Days
Time to Systemic Juvenile Idiopathic Arthritis (sJIA) Disease Flare: Double-Blind Phase
DaysTofacitinib 5mg BID DBPlacebo DB
Time to Systemic Juvenile Idiopathic Arthritis (sJIA) Disease Flare: Double-Blind PhaseNA (186.0 to NA)295.0 (99.0 to NA)
Statistical analysis
  • Tofacitinib 5mg BID DB vs Placebo DB · Unstratified log-rank test · p = = 0.1171 (1-sided p-value is provided.) · Hazard ratio (hr): 0.633 · 95% CI 0.296 to 1.354Hazard ratio and 95% CI was based on Cox proportional hazards model with treatment group as covariate. Hazard ratio \< 1 indicates a reduction in hazard ratio in favor of Tofacitinib 5 mg BID to Placebo.
SecondaryProbability of Occurrence of sJIA Disease Flare at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52: Double-Blind Phase

sJIA Flare was defined as at least one of the following criteria: recurrence of fever (\>38° C/100.4 degree F) on 2 or more consecutive days) was considered due to SJIA activity. Worsening of 30% or more in three or more of the six variables: number of joints with active arthritis and limited range of motion, disease activity, parent child evaluation of overall well-being, functional ability (CHAQ Disability Index), ESR. of the JIA core set with no more than one variable of the JIA core set improving by 30% compared to the day of randomization into the withdrawal phase. Probability of occurrence of sJIA disease flare with 95% CI were estimated using Kaplan-Meier method and reported in this outcome measure.

Time frame:
DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Reported as:
Number · Percentage probability of occurrence
Probability of Occurrence of sJIA Disease Flare at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52: Double-Blind Phase
Percentage probability of occurrenceTofacitinib 5mg BID DBPlacebo DB
DB Week 47.16.5
DB Week 814.322.6
DB Week 1221.432.3
DB Week 1625.038.7
DB Week 2032.145.4
DB Week 2432.145.4
DB Week 2835.945.4
DB Week 3235.949.9
DB Week 3640.549.9
DB Week 4040.549.9
DB Week 4440.555.5
DB Week 4840.555.5
DB Week 5240.555.5
Statistical analysis
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 0.7 · 95% CI -12.2 to 13.6The 95% CIs for the differences between the treatment groups were generated using Greenwood's formula.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -8.3 · 95% CI -27.9 to 11.3The 95% CIs for the differences between the treatment groups were generated using Greenwood's formula.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -10.8 · 95% CI -33.2 to 11.6The 95% CIs for the differences between the treatment groups were generated using Greenwood's formula.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -13.7 · 95% CI -37.2 to 9.8The 95% CIs for the differences between the treatment groups were generated using Greenwood's formula.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -13.2 · 95% CI -37.9 to 11.5The 95% CIs for the differences between the treatment groups were generated using Greenwood's formula.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -13.2 · 95% CI -37.9 to 11.5The 95% CIs for the differences between the treatment groups were generated using Greenwood's formula.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -9.4 · 95% CI -34.5 to 15.6The 95% CIs for the differences between the treatment groups were generated using Greenwood's formula.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -14.0 · 95% CI -39.5 to 11.5The 95% CIs for the differences between the treatment groups were generated using Greenwood's formula.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -9.4 · 95% CI -35.5 to 16.7The 95% CIs for the differences between the treatment groups were generated using Greenwood's formula.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -9.4 · 95% CI -35.5 to 16.7The 95% CIs for the differences between the treatment groups were generated using Greenwood's formula.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -15.0 · 95% CI -41.8 to 11.8The 95% CIs for the differences between the treatment groups were generated using Greenwood's formula.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -15.0 · 95% CI -41.8 to 11.8The 95% CIs for the differences between the treatment groups were generated using Greenwood's formula.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -15.0 · 95% CI -41.8 to 11.8The 95% CIs for the differences between the treatment groups were generated using Greenwood's formula.
SecondaryPercentage of Participants Who Achieved Successful Corticosteroid Tapering: at the End of Open-label Phase Part 2

A successfully tapered participant was considered as the one that completed part 2 of the OL by reaching their target corticosteroid dose and maintained an adapted JIA American College of Rheumatology (ACR) 30 response for four weeks on this dose. The target CS dose at the end of part 2 included less than equal to (\<=) 0.5 milligram/kilogram/day (mg/kg/day) up to a maximum dose of 15 milligram/ day (mg/day) oral prednisone (or equivalent) for CS\>0.8 mg/kg/day oral prednisone; reduction to \<=0.3 mg/kg/day up to a maximum of 12 mg/day oral prednisone (or equivalent) for CS \<=0.8 mg/kg/day to greater than equal to (\>=) 0.5 mg/kg/day oral prednisone (or equivalent) and \<=0.2 mg/kg/day up to a maximum dose of 10 mg/day oral prednisone (or equivalent) for CS \<0.5 mg/kg/day-CS˃0.2 mg/kg/day oral prednisone (or equivalent). 95% CI was based on normal approximation.

Time frame:
From end of OL Part 1 to up to 24 weeks in OL Part 2
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Successful Corticosteroid Tapering: at the End of Open-label Phase Part 2
Percentage of participantsTofacitinib 5mg BID OL Part 2
Percentage of Participants Who Achieved Successful Corticosteroid Tapering: at the End of Open-label Phase Part 270.37 (58.19 to 82.55)
SecondaryPercentage of Participants Who Achieved Corticosteroid Dose of <= 0.2 mg/kg/Day or 10 mg/Day: at the End of Open-label Phase Part 2

95% CI was based on normal approximation.

Time frame:
From end of OL Part 1 to up to 24 weeks in OL Part 2
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Corticosteroid Dose of <= 0.2 mg/kg/Day or 10 mg/Day: at the End of Open-label Phase Part 2
Percentage of participantsTofacitinib 5mg BID OL Part 2
Percentage of Participants Who Achieved Corticosteroid Dose of <= 0.2 mg/kg/Day or 10 mg/Day: at the End of Open-label Phase Part 259.26 (46.15 to 72.36)
SecondaryPercentage of Participants With Adapted JIA ACR 30/50/70/90/100 Response at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase

Adapted JIA ACR 30,50,70,90,100 response=absence of fever due to sJIA in preceding 7 days along with improvement of \>=30,50,70,90,100%, respectively in at least 3 out of 6 JIA core set variables with no more than 1 JIA core set variable worsening by \>=30%.Variables included: number of joints with active arthritis(any joint with swelling, or absence of swelling, limitation of motion accompanied by either pain on motion or tenderness);number of joints with limited range of motion; physician global evaluation of disease activity on VAS from 0=no disease activity to 10=very severe disease activity, higher scores:greater disease activity; parent/legal guardian/child evaluation of overall well-being on VAS from 0=very well to 10mm=very poor, higher scores: worsen condition; functional ability (Disability Index ranged from 0=no or minimal physical dysfunction, 3=very severe physical dysfunction, higher scores:more physical dysfunction;ESR (mm/hr).Missing response was imputed as non-response.

Time frame:
DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Reported as:
Number · Percentage of participants
Percentage of Participants With Adapted JIA ACR 30/50/70/90/100 Response at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase
Percentage of participantsTofacitinib 5mg BID DBPlacebo DB
ACR30:DB Week 482.14 (67.96 to 96.33)93.55 (84.90 to 100)
ACR30:DB Week 882.14 (67.96 to 96.33)80.65 (66.74 to 94.55)
ACR30:DB Week 1271.43 (54.70 to 88.16)70.97 (54.99 to 86.95)
ACR30:DB Week 1671.43 (54.70 to 88.16)61.29 (44.14 to 78.44)
ACR30:DB Week 2067.86 (50.56 to 85.16)51.61 (34.02 to 69.21)
ACR30:DB Week 2464.29 (46.54 to 82.03)54.84 (37.32 to 72.36)
ACR30:DB Week 2860.71 (42.62 to 78.80)51.61 (34.02 to 69.21)
ACR30:DB Week 3260.71 (42.62 to 78.80)51.61 (34.02 to 69.21)
ACR30:DB Week 3660.71 (42.62 to 78.80)51.61 (34.02 to 69.21)
ACR30:DB Week 4060.71 (42.62 to 78.80)51.61 (34.02 to 69.21)
ACR30:DB Week 4460.71 (42.62 to 78.80)51.61 (34.02 to 69.21)
ACR30:DB Week 4860.71 (42.62 to 78.80)48.39 (30.79 to 65.98)
ACR30:DB Week 5260.71 (42.62 to 78.80)48.39 (30.79 to 65.98)
ACR50:DB Week 482.14 (67.96 to 96.33)93.55 (84.90 to 100)
ACR50:DB Week 882.14 (67.96 to 96.33)77.42 (62.70 to 92.14)
ACR50:DB Week 1271.43 (54.70 to 88.16)70.97 (54.99 to 86.95)
ACR50:DB Week 1671.43 (54.70 to 88.16)58.06 (40.69 to 75.44)
ACR50:DB Week 2067.86 (50.56 to 85.16)48.39 (30.79 to 65.98)
ACR50:DB Week 2464.29 (46.54 to 82.03)54.84 (37.32 to 72.36)
ACR50:DB Week 2860.71 (42.62 to 78.80)51.61 (34.02 to 69.21)
ACR50:DB Week 3260.71 (42.62 to 78.80)51.61 (34.02 to 69.21)
ACR50:DB Week 3660.71 (42.62 to 78.80)51.61 (34.02 to 69.21)
ACR50:DB Week 4060.71 (42.62 to 78.80)51.61 (34.02 to 69.21)
ACR50:DB Week 4460.71 (42.62 to 78.80)48.39 (30.79 to 65.98)
ACR50:DB Week 4860.71 (42.62 to 78.80)48.39 (30.79 to 65.98)
ACR50:DB Week 5260.71 (42.62 to 78.80)48.39 (30.79 to 65.98)
ACR70:DB Week 457.14 (38.81 to 75.47)70.97 (54.99 to 86.95)
ACR70:DB Week 867.86 (50.56 to 85.16)77.42 (62.70 to 92.14)
ACR70:DB Week 1264.29 (46.54 to 82.03)64.52 (47.67 to 81.36)
ACR70:DB Week 1660.71 (42.62 to 78.80)54.84 (37.32 to 72.36)
ACR70:DB Week 2064.29 (46.54 to 82.03)45.16 (27.64 to 62.68)
ACR70:DB Week 2453.57 (35.10 to 72.04)51.61 (34.02 to 69.21)
ACR70:DB Week 2857.14 (38.81 to 75.47)41.94 (24.56 to 59.31)
ACR70:DB Week 3260.71 (42.62 to 78.80)48.39 (30.79 to 65.98)
ACR70:DB Week 3660.71 (42.62 to 78.80)51.61 (34.02 to 69.21)
ACR70:DB Week 4060.71 (42.62 to 78.80)48.39 (30.79 to 65.98)
ACR70:DB Week 4460.71 (42.62 to 78.80)48.39 (30.79 to 65.98)
ACR70:DB Week 4860.71 (42.62 to 78.80)48.39 (30.79 to 65.98)
ACR70:DB Week 5260.71 (42.62 to 78.80)48.39 (30.79 to 65.98)
ACR90:DB Week 428.57 (11.84 to 45.30)48.39 (30.79 to 65.98)
ACR90:DB Week 821.43 (6.23 to 36.63)38.71 (21.56 to 55.86)
ACR90:DB Week 1225.00 (8.96 to 41.04)38.71 (21.56 to 55.86)
ACR90:DB Week 1625.00 (8.96 to 41.04)29.03 (13.05 to 45.01)
ACR90:DB Week 2021.43 (6.23 to 36.63)29.03 (13.05 to 45.01)
ACR90:DB Week 2421.43 (6.23 to 36.63)25.81 (10.40 to 41.21)
ACR90:DB Week 2817.86 (3.67 to 32.04)25.81 (10.40 to 41.21)
ACR90:DB Week 3214.29 (1.32 to 27.25)29.03 (13.05 to 45.01)
ACR90:DB Week 3628.57 (11.84 to 45.30)35.48 (18.64 to 52.33)
ACR90:DB Week 4028.57 (11.84 to 45.30)32.26 (15.80 to 48.71)
ACR90:DB Week 4428.57 (11.84 to 45.30)29.03 (13.05 to 45.01)
ACR90:DB Week 4828.57 (11.84 to 45.30)29.03 (13.05 to 45.01)
ACR90:DB Week 5228.57 (11.84 to 45.30)29.03 (13.05 to 45.01)
ACR100:DB Week 414.29 (1.32 to 27.25)35.48 (18.64 to 52.33)
ACR100:DB Week 810.71 (0 to 22.17)29.03 (13.05 to 45.01)
ACR100:DB Week 1214.29 (1.32 to 27.25)25.81 (10.40 to 41.21)
ACR100:DB Week 1617.86 (3.67 to 32.04)25.81 (10.40 to 41.21)
ACR100:DB Week 2014.29 (1.32 to 27.25)12.90 (1.10 to 24.70)
ACR100:DB Week 2417.86 (3.67 to 32.04)19.35 (5.45 to 33.26)
ACR100:DB Week 2814.29 (1.32 to 27.25)22.58 (7.86 to 37.30)
ACR100:DB Week 3210.71 (0 to 22.17)25.81 (10.40 to 41.21)
ACR100:DB Week 3614.29 (1.32 to 27.25)25.81 (10.40 to 41.21)
ACR100:DB Week 4021.43 (6.23 to 36.63)29.03 (13.05 to 45.01)
ACR100:DB Week 4421.43 (6.23 to 36.63)25.81 (10.40 to 41.21)
ACR100:DB Week 4825.00 (8.96 to 41.04)25.81 (10.40 to 41.21)
ACR100:DB Week 5225.00 (8.96 to 41.04)25.81 (10.40 to 41.21)
Statistical analysis
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -11.41 · 95% CI -28.02 to 5.21The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 1.50 · 95% CI -18.37 to 21.36The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 0.46 · 95% CI -22.68 to 23.60The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 10.14 · 95% CI -13.82 to 34.10The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 16.24 · 95% CI -8.43 to 40.92The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 9.45 · 95% CI -15.49 to 34.39The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 9.10 · 95% CI -16.13 to 34.33The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 9.10 · 95% CI -16.13 to 34.33The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 9.10 · 95% CI -16.13 to 34.33The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 9.10 · 95% CI -16.13 to 34.33The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 9.10 · 95% CI -16.13 to 34.33The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 12.33 · 95% CI -12.91 to 37.56The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 12.33 · 95% CI -12.91 to 37.56The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -11.41 · 95% CI -28.02 to 5.21The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 4.72 · 95% CI -15.72 to 25.17The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 0.46 · 95% CI -22.68 to 23.60The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 13.36 · 95% CI -10.76 to 37.48The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 19.47 · 95% CI -5.20 to 44.14The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 9.45 · 95% CI -15.49 to 34.39The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 9.10 · 95% CI -16.13 to 34.33The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 9.10 · 95% CI -16.13 to 34.33The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 9.10 · 95% CI -16.13 to 34.33The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 9.10 · 95% CI -16.13 to 34.33The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 12.33 · 95% CI -12.91 to 37.56The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 12.33 · 95% CI -12.91 to 37.56The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 12.33 · 95% CI -12.91 to 37.56The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -13.82 · 95% CI -38.14 to 10.49The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -9.56 · 95% CI -32.28 to 13.15The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -0.23 · 95% CI -24.70 to 24.24The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 5.88 · 95% CI -19.31 to 31.06The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 19.12 · 95% CI -5.81 to 44.06The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 1.96 · 95% CI -23.55 to 27.47The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 15.21 · 95% CI -10.05 to 40.46The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 12.33 · 95% CI -12.91 to 37.56The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 9.10 · 95% CI -16.13 to 34.33The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 12.33 · 95% CI -12.91 to 37.56The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 12.33 · 95% CI -12.91 to 37.56The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 12.33 · 95% CI -12.91 to 37.56The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 12.33 · 95% CI -12.91 to 37.56The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -19.82 · 95% CI -44.09 to 4.46The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -17.28 · 95% CI -40.19 to 5.63The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -7.60 · 95% CI -29.66 to 14.45The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -13.71 · 95% CI -37.19 to 9.77The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -4.03 · 95% CI -26.67 to 18.61The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -14.75 · 95% CI -35.32 to 5.83The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -4.38 · 95% CI -26.02 to 17.26The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -7.95 · 95% CI -28.89 to 12.99The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -6.91 · 95% CI -30.65 to 16.83The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -3.69 · 95% CI -27.16 to 19.78The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -0.46 · 95% CI -23.60 to 22.68The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -0.46 · 95% CI -23.60 to 22.68The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -0.46 · 95% CI -23.60 to 22.68The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -21.20 · 95% CI -42.45 to 0.05The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -18.32 · 95% CI -37.98 to 1.34The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -11.52 · 95% CI -31.65 to 8.61The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -7.95 · 95% CI -28.89 to 12.99The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 1.38 · 95% CI -16.15 to 18.91The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -1.50 · 95% CI -21.36 to 18.37The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -8.29 · 95% CI -27.91 to 11.32The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -15.09 · 95% CI -34.29 to 4.10The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -11.52 · 95% CI -31.65 to 8.61The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -7.60 · 95% CI -29.66 to 14.45The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -4.38 · 95% CI -26.02 to 17.26The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -0.81 · 95% CI -23.04 to 21.43The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -0.81 · 95% CI -23.04 to 21.43The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
SecondaryPercentage of Participants With Adapted JIA American College of Rheumatology (ACR) 30/50/70/90/100 Response at Part 1 Day 7, Weeks 2, 4, 8, 12, and 16: Open-Label Phase Part 1

Adapted JIA ACR 30,50,70,90,100 response=absence of fever due to sJIA in preceding 7 days along with improvement of \>=30,50,70,90,100%, respectively in at least 3 out of 6 JIA core set variables with no more than 1 JIA core set variable worsening by \>=30%.Variables included: number of joints with active arthritis(any joint with swelling, or absence of swelling, limitation of motion accompanied by either pain on motion or tenderness);number of joints with limited range of motion; physician global evaluation of disease activity on VAS from 0=no disease activity to 10=very severe disease activity, higher scores: greater disease activity; parent/legal guardian/child evaluation of overall well-being on VAS from 0=very well to 10mm=very poor, higher scores: worsen condition; functional ability (Disability Index ranged from 0=no or minimal physical dysfunction, 3=very severe physical dysfunction, higher scores: more physical dysfunction; ESR (mm/hr).

Time frame:
Part 1 Day 7, Part 1 Weeks 2, 4, 8, 12, and 16
Reported as:
Number · Percentage of participants
Percentage of Participants With Adapted JIA American College of Rheumatology (ACR) 30/50/70/90/100 Response at Part 1 Day 7, Weeks 2, 4, 8, 12, and 16: Open-Label Phase Part 1
Percentage of participantsTofacitinib 5mg BID OL Part 1
ACR30: Part 1 Day 726.26 (17.59 to 34.93)
ACR30: Part 1 Week 242.42 (32.69 to 52.16)
ACR30: Part 1 Week 468.04 (58.76 to 77.32)
ACR30: Part 1 Week 886.59 (79.21 to 93.96)
ACR30:Part 1 Week 1290.91 (82.41 to 99.40)
ACR30: Part 1 Week 1683.33 (68.42 to 98.24)
ACR50:Part 1 Day 718.18 (10.58 to 25.78)
ACR50:Part 1 Week 228.28 (19.41 to 37.15)
ACR50:Part 1 Week 444.33 (34.44 to 54.22)
ACR50:Part 1 Week 859.04 (48.46 to 69.62)
ACR50:Part 1 Week 1279.55 (67.63 to 91.46)
ACR50:Part 1 Week 1675.00 (57.68 to 92.32)
ACR70:Part 1 Day 710.10 (4.16 to 16.04)
ACR70:Part 1 Week 216.16 (8.91 to 23.41)
ACR70:Part 1 Week 419.59 (11.69 to 27.49)
ACR70:Part 1 Week 834.15 (23.88 to 44.41)
ACR70:Part 1 Week 1238.64 (24.25 to 53.02)
ACR70:Part 1 Week 1633.33 (14.47 to 52.19)
ACR90:Part 1 Day 75.05 (0.74 to 9.36)
ACR90:Part 1 Week 26.06 (1.36 to 10.76)
ACR90:Part 1 Week 411.34 (5.03 to 17.65)
ACR90:Part 1 Week 818.29 (9.92 to 26.66)
ACR90:Part 1 Week 1215.91 (5.10 to 26.72)
ACR90:Part 1 Week 1616.67 (1.76 to 31.58)
ACR100:Part 1 Day 73.03 (0 to 6.41)
ACR100:Part 1 Week 25.05 (0.74 to 9.36)
ACR100:Part 1 Week 48.25 (2.77 to 13.72)
ACR100:Part 1 Week 813.41 (6.04 to 20.79)
ACR100:Part 1 Week 129.09 (0.60 to 17.59)
ACR100:Part 1 Week 168.33 (0 to 19.39)
SecondaryPercentage of Participants With Adapted JIA ACR 30/50/70/90/100 Response at Part 2 Weeks 4, 8, 12, 16, 20 and 24: Open-label Phase Part 2

Adapted JIA ACR 30,50,70,90,100 response=absence of fever due to sJIA in preceding 7 days along with improvement of \>=30,50,70,90,100%, respectively in at least 3 out of 6 JIA core set variables with no more than 1 JIA core set variable worsening by \>=30%.Variables included: number of joints with active arthritis(any joint with swelling, or absence of swelling, limitation of motion accompanied by either pain on motion or tenderness);number of joints with limited range of motion; physician global evaluation of disease activity on VAS from 0=no disease activity to 10=very severe disease activity, higher scores: greater disease activity; parent/legal guardian/child evaluation of overall well-being on VAS from 0=very well to 10mm=very poor, higher scores: worsen condition; functional ability (Disability Index ranged from 0=no or minimal physical dysfunction, 3=very severe physical dysfunction, higher scores: more physical dysfunction; ESR (mm/hr).

Time frame:
Part 2 Weeks 4, 8, 12, 16, 20 and 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Adapted JIA ACR 30/50/70/90/100 Response at Part 2 Weeks 4, 8, 12, 16, 20 and 24: Open-label Phase Part 2
Percentage of participantsTofacitinib 5mg BID OL Part 2
ACR30:Part 2 Week 490.00 (81.68 to 98.32)
ACR30:Part 2 Week 887.50 (77.25 to 97.75)
ACR30:Part 2 Week 1290.32 (79.91 to 100)
ACR30:Part 2 week 1686.96 (73.19 to 100)
ACR30:Part 2 Week 20100 (100 to 100)
ACR30:Part 2 Week 24100 (100 to 100)
ACR50:Part 2 Week 486.00 (76.38 to 95.62)
ACR50:Part 2 Week 877.50 (64.56 to 90.44)
ACR50:Part 2 Week 1280.65 (66.74 to 94.55)
ACR50:Part 2 Week 1673.91 (55.97 to 91.86)
ACR50:Part 2 Week 2092.31 (77.82 to 100)
ACR50:Part 2 Week 24100 (100 to 100)
ACR70:Part 2 Week 468.00 (55.07 to 80.93)
ACR70:Part 2 Week 867.50 (52.98 to 82.02)
ACR70:Part 2 Week 1270.97 (54.99 to 86.95)
ACR70:Part 2 Week 1673.91 (55.97 to 91.86)
ACR70:Part 2 Week 2092.31 (77.82 to 100)
ACR70:Part 2 Week 2466.67 (13.32 to 100)
ACR90:Part 2 Week 432.00 (19.07 to 44.93)
ACR90:Part 2 Week 827.50 (13.66 to 41.34)
ACR90:Part 2 Week 1222.58 (7.86 to 37.30)
ACR90:Part 2 Week 1634.78 (15.32 to 54.25)
ACR90:Part 2 Week 2053.85 (26.75 to 80.95)
ACR90:Part 2 Week 2433.33 (0 to 86.68)
ACR100:Part 2 Week 428.00 (15.55 to 40.45)
ACR100:Part 2 Week 827.50 (13.66 to 41.34)
ACR100:Part 2 Week 1216.13 (3.18 to 29.08)
ACR100:Part 2 Week 1626.09 (8.14 to 44.03)
ACR100:Part 2 Week 2038.46 (12.01 to 64.91)
ACR100:Part 2 Week 2433.33 (0 to 86.68)
SecondaryPercentage of Participants With Fever Attributed to sJIA at Part 1 Days 3, 7 and 14: Open-Label Phase Part 1

Fever was defined as an oral temperature of ˃38 degree Celsius/100.4 degree Fahrenheit. 95% CI was based on normal approximation.

Time frame:
Part 1 Days 3, 7 and 14
Reported as:
Number · Percentage of participants
Percentage of Participants With Fever Attributed to sJIA at Part 1 Days 3, 7 and 14: Open-Label Phase Part 1
Percentage of participantsTofacitinib 5mg BID OL Part 1
Part 1 Day 33.13 (0 to 6.61)
Part 1 Day 71.03 (0 to 3.04)
Part 1 Day 144.12 (0.17 to 8.08)
SecondaryPercentage of Participants With C-Reactive Protein (CRP) <= 10 mg/L at Baseline, Part 1 Days 3, 7, Weeks 2, 4, 8, 12, 16: Open-Label Phase Part 1

Percentage of participants with CRP \<= 10 milligrams per liter (mg/L) along with 95% CI based on normal approximation is reported in this outcome.

Time frame:
Baseline (last value collected prior to Day 1 of study treatment), Part 1 Days 3, 7, Part 1 Weeks 2, 4, 8, 12, 16
Reported as:
Number · Percentage of participants
Percentage of Participants With C-Reactive Protein (CRP) <= 10 mg/L at Baseline, Part 1 Days 3, 7, Weeks 2, 4, 8, 12, 16: Open-Label Phase Part 1
Percentage of participantsTofacitinib 5mg BID OL Part 1
Baseline30.00 (21.02 to 38.98)
Part 1 Day 332.63 (23.20 to 42.06)
Part 1 Day 745.36 (35.45 to 55.27)
Part 1 Week 249.48 (39.53 to 59.43)
Part 1 Week 455.67 (45.78 to 65.56)
Part 1 Week 860.00 (49.26 to 70.74)
Part 1 Week 1259.09 (44.56 to 73.62)
Part 1 Week 1641.67 (21.94 to 61.39)
SecondaryPercentage of Participants With C-Reactive Protein (CRP) <= 10 mg/L at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2

Percentage of participants with CRP \<= 10 mg/L along with 95% CI based on normal approximation is reported in this outcome.

Time frame:
Part 2 Weeks 4, 8, 12, 16, 20, 24
Reported as:
Number · Percentage of participants
Percentage of Participants With C-Reactive Protein (CRP) <= 10 mg/L at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2
Percentage of participantsTofacitinib 5mg BID OL Part 2
Part 2 Week 468.00 (55.07 to 80.93)
Part 2 Week 862.50 (47.50 to 77.50)
Part 2 Week 1251.61 (34.02 to 69.21)
Part 2 Week 1654.55 (33.74 to 75.35)
Part 2 Week 2076.92 (54.02 to 99.83)
Part 2 Week 2433.33 (0 to 86.68)
SecondaryPercentage of Participants With Absence of Fever Due to sJIA at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-label Phase Part 1

Percentage of participants with absence of fever along with 95% CI based on normal approximation is reported in this outcome.

Time frame:
Part 1 Day 7, Part 1 Weeks 2, 4, 8, 12, 16
Reported as:
Number · Percentage of participants
Percentage of Participants With Absence of Fever Due to sJIA at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-label Phase Part 1
Percentage of participantsTofacitinib 5mg BID OL Part 1
Part 1 Day 783.51 (76.12 to 90.89)
Part 1 Week 282.47 (74.91 to 90.04)
Part 1 Week 490.72 (84.95 to 96.50)
Part 1 Week 896.39 (92.37 to 100)
Part 1 Week 12100 (100 to 100)
Part 1 Week 1695.83 (87.84 to 100)
SecondaryPercentage of Participants With Absence of Fever Due to sJIA at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2

Percentage of participants with absence of fever along with 95% CI based on normal approximation is reported in this outcome.

Time frame:
Part 2 Weeks 4, 8, 12, 16, 20 and 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Absence of Fever Due to sJIA at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2
Percentage of participantsTofacitinib 5mg BID OL Part 2
Part 2 Week 498.00 (94.12 to 100)
Part 2 Week 892.31 (83.94 to 100)
Part 2 Week 1296.77 (90.55 to 100)
Part 2 Week 1690.91 (78.90 to 100)
Part 2 Week 20100 (100 to 100)
Part 2 Week 24100 (100 to 100)
SecondaryPercentage of Participants With Absence of Fever Due to sJIA at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52: Double Blind Phase

Percentage of participants with absence of fever due sJIA is reported in this outcome. Missing response was imputed as non-response.

Time frame:
DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Reported as:
Number · Percentage of participants
Percentage of Participants With Absence of Fever Due to sJIA at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52: Double Blind Phase
Percentage of participantsTofacitinib 5mg BID DBPlacebo DB
DB Week 485.71 (72.75 to 98.68)93.55 (84.90 to 100)
DB Week 885.71 (72.75 to 98.68)80.65 (66.74 to 94.55)
DB Week 1275.00 (58.96 to 91.04)74.19 (58.79 to 89.60)
DB Week 1671.43 (54.70 to 88.16)61.29 (44.14 to 78.44)
DB Week 2067.86 (50.56 to 85.16)51.61 (34.02 to 69.21)
DB Week 2464.29 (46.54 to 82.03)54.84 (37.32 to 72.36)
DB Week 2860.71 (42.62 to 78.80)51.61 (34.02 to 69.21)
DB Week 3260.71 (42.62 to 78.80)51.61 (34.02 to 69.21)
DB Week 3660.71 (42.62 to 78.80)51.61 (34.02 to 69.21)
DB Week 4060.71 (42.62 to 78.80)51.61 (34.02 to 69.21)
DB Week 4460.71 (42.62 to 78.80)51.61 (34.02 to 69.21)
DB Week 4860.71 (42.62 to 78.80)48.39 (30.79 to 65.98)
DB Week 5260.71 (42.62 to 78.80)48.39 (30.79 to 65.98)
Statistical analysis
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -7.83 · 95% CI -23.42 to 7.75The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 5.07 · 95% CI -13.94 to 24.08The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 0.81 · 95% CI -21.43 to 23.04The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 10.14 · 95% CI -13.82 to 34.10The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 16.24 · 95% CI -8.43 to 40.92The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 9.45 · 95% CI -15.49 to 34.39The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 9.10 · 95% CI -16.13 to 34.33The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 9.10 · 95% CI -16.13 to 34.33The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 9.10 · 95% CI -16.13 to 34.33The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 9.10 · 95% CI -16.13 to 34.33The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 9.10 · 95% CI -16.13 to 34.33The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 12.33 · 95% CI -12.91 to 37.56The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 12.33 · 95% CI -12.91 to 37.56The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
SecondaryTime to First Adapted JIA ACR 30 Response: Open-label Phase Part 1

Time to the first adapted JIA ACR 30 response was measured in number of days since Day 1 (day of adapted JIA ACR 30 response - Day 1 + 1) in the OL Phase Part 1. Participants that did not achieve an adapted JIA ACR30 response defined as absence of fever due to sJIA \[temperature =\<38 degree Celsius/100.4 degree F in the preceding 7 days along with an improvement of at least 30% from baseline (Day 1 of study drug before first tofacitinib administration) in at least 3 of the 6 JIA core components, with worsening of \>=30 in no more than 1 of the remaining components, which in Part 1 (withdrew from the study) were censored at their last available response assessment in Part 1. 95% CI was based on the Brookmeyer and Crowley Method.

Time frame:
From Day 1 up to 16 weeks
Reported as:
Median · Days
Time to First Adapted JIA ACR 30 Response: Open-label Phase Part 1
DaysTofacitinib 5mg BID OL Part 1
Time to First Adapted JIA ACR 30 Response: Open-label Phase Part 127.0 (15.0 to 29.0)
SecondaryChange From Open Label Baseline in Juvenile Arthritis Disease Activity Score (JADAS-27) Erythrocyte Sedimentation Rate (ESR) at Part 1 Day 7, Part 1 Weeks 2, 4, 8, 12 and 16: Open-Label Phase Part 1

JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 ESR score was determined based on four components: Physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ) assessed on a VAS of 0 \[very well\] to 10 \[very poor\], ESR (value normalized to 0 to 10 scale) and number of joints with active disease (27 joint assessment ranging from 0 to 27). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.

Time frame:
Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 1 Day 7, Part 1 Weeks 2, 4, 8, 12 and 16
Reported as:
Mean · Units on a scale
Change From Open Label Baseline in Juvenile Arthritis Disease Activity Score (JADAS-27) Erythrocyte Sedimentation Rate (ESR) at Part 1 Day 7, Part 1 Weeks 2, 4, 8, 12 and 16: Open-Label Phase Part 1
Units on a scaleTofacitinib 5mg BID OL Part 1
Part 1 Day 7-5.64 ± 5.20
Part 1 Week 2-8.57 ± 5.97
Part 1 Week 4-11.95 ± 6.53
Part 1 Week 8-15.09 ± 7.27
Part 1 Week 12-15.77 ± 7.24
Part 1 Week 16-14.08 ± 6.09
SecondaryChange From Open-Label Baseline in JADAS-27 CRP at Part 1 Day 7, Part 1 Weeks 2, 4, 8, 12 and 16: Open-Label Phase Part 1

JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score was determined based on four components: physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), CRP (value normalized to 0 to 10 scale) and number of joints with active disease (27 joint assessment ranging from 0 to 27). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.

Time frame:
Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 1 Day 7, Part 1 Weeks 2, 4, 8, 12 and 16
Reported as:
Mean · Units on a scale
Change From Open-Label Baseline in JADAS-27 CRP at Part 1 Day 7, Part 1 Weeks 2, 4, 8, 12 and 16: Open-Label Phase Part 1
Units on a scaleTofacitinib 5mg BID OL Part 1
Part 1 Day 7-6.25 ± 5.53
Part 1 Week 2-8.55 ± 6.10
Part 1 Week 4-11.88 ± 7.28
Part 1 Week 8-15.07 ± 8.46
Part 1 Week 12-15.19 ± 7.73
Part 1 Week 16-13.10 ± 6.37
SecondaryChange From Open-Label Baseline in JADAS-27 ESR at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2

JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 ESR score was determined based on four components: physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), ESR (value normalized to 0 to 10 scale) and number of joints with active disease (27 joint assessment ranging from 0 to 27). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.

Time frame:
Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 2 Weeks 4, 8, 12, 16, 20 and 24
Reported as:
Mean · Units on a scale
Change From Open-Label Baseline in JADAS-27 ESR at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2
Units on a scaleTofacitinib 5mg BID OL Part 2
Part 2 Week 4-17.05 ± 8.18
Part 2 Week 8-17.13 ± 8.14
Part 2 Week 12-18.17 ± 7.74
Part 2 Week 16-18.89 ± 7.56
Part 2 Week 20-21.14 ± 5.78
Part 2 Week 24-22.17 ± 7.58
SecondaryChange From Open-Label Baseline in JADAS-27 CRP at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2

JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score was determined based on four components: physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), CRP (value normalized to 0 to 10 scale) and number of joints with active disease (27 joint assessment ranging from 0 to 27). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.

Time frame:
Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 2 Weeks 4, 8, 12, 16, 20 and 24
Reported as:
Mean · Units on a scale
Change From Open-Label Baseline in JADAS-27 CRP at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2
Units on a scaleTofacitinib 5mg BID OL Part 2
Part 2 Week 4-17.16 ± 8.87
Part 2 Week 8-17.44 ± 8.03
Part 2 Week 12-18.99 ± 7.67
Part 2 Week 16-20.31 ± 6.41
Part 2 Week 20-22.16 ± 7.05
Part 2 Week 24-25.61 ± 9.82
SecondaryChange From Double-Blind Baseline in JADAS-27 ESR at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase

JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 ESR score was determined based on four components: Physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ) (assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), ESR (value normalized to 0 to 10 scale) and number of joints with active disease (27 joint assessment ranging from 0 to 27). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.

Time frame:
DB Baseline (at randomization on Day 1 in DB phase), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Reported as:
Least squares mean · Units on a scale
Change From Double-Blind Baseline in JADAS-27 ESR at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase
Units on a scaleTofacitinib 5mg BID DBPlacebo DB
DB Week 41.07 ± 0.841.08 ± 0.79
DB Week 81.75 ± 1.080.81 ± 1.06
DB Week 121.47 ± 1.461.71 ± 1.40
DB Week 160.43 ± 1.031.29 ± 1.04
DB Week 20-1.04 ± 0.650.05 ± 0.69
DB Week 24-0.49 ± 0.57-0.79 ± 0.60
DB Week 282.58 ± 2.053.86 ± 2.25
DB Week 32-0.21 ± 0.77-0.68 ± 0.83
DB Week 36-1.52 ± 0.50-1.26 ± 0.54
DB Week 40-0.23 ± 0.91-0.96 ± 0.96
DB Week 44-1.67 ± 0.75-0.83 ± 0.79
DB Week 48-2.29 ± 0.38-2.06 ± 0.60
DB Week 52-2.41 ± 0.60-1.65 ± 1.07
Statistical analysis
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.01 · 95% CI -2.40 to 2.38
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.94 · 95% CI -2.25 to 4.12
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.24 · 95% CI -4.54 to 4.06
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.86 · 95% CI -3.99 to 2.28
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -1.09 · 95% CI -3.12 to 0.94
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.30 · 95% CI -1.46 to 2.06
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -1.28 · 95% CI -7.85 to 5.29
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.48 · 95% CI -1.98 to 2.93
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.26 · 95% CI -1.86 to 1.35
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.73 · 95% CI -2.18 to 3.63
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.83 · 95% CI -3.22 to 1.56
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.23 · 95% CI -1.76 to 1.30
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.75 · 95% CI -3.43 to 1.93
SecondaryChange From Double-Blind Baseline in JADAS-27 CRP at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase

JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score was determined based on four components: Physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), CRP (value normalized to 0 to 10 scale) and number of joints with active disease (27 joint assessment ranging from 0 to 27). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.

Time frame:
DB Baseline (at randomization on Day 1 in DB phase), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Reported as:
Least squares mean · Units on a scale
Change From Double-Blind Baseline in JADAS-27 CRP at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase
Units on a scaleTofacitinib 5mg BID DBPlacebo DB
DB Week 41.62 ± 0.960.71 ± 0.90
DB Week 82.12 ± 0.950.01 ± 0.93
DB Week 121.78 ± 1.461.80 ± 1.40
DB Week 160.84 ± 1.091.95 ± 1.08
DB Week 20-0.17 ± 0.840.36 ± 0.87
DB Week 241.58 ± 1.04-0.26 ± 1.08
DB Week 282.64 ± 1.862.72 ± 2.04
DB Week 320.49 ± 0.991.18 ± 1.07
DB Week 36-1.59 ± 0.50-1.24 ± 0.53
DB Week 400.38 ± 1.150.41 ± 1.21
DB Week 44-1.09 ± 0.991.50 ± 1.02
DB Week 48-2.04 ± 0.51-1.23 ± 0.76
DB Week 52-2.31 ± 0.60-1.85 ± 1.10
Statistical analysis
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.90 · 95% CI -1.80 to 3.61
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 2.11 · 95% CI -0.64 to 4.86
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.02 · 95% CI -4.25 to 4.21
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -1.12 · 95% CI -4.32 to 2.09
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.53 · 95% CI -3.04 to 1.98
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 1.84 · 95% CI -1.29 to 4.97
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.08 · 95% CI -5.89 to 5.72
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.69 · 95% CI -3.79 to 2.41
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.35 · 95% CI -1.89 to 1.19
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.03 · 95% CI -3.63 to 3.58
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -2.59 · 95% CI -5.67 to 0.49
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.82 · 95% CI -2.82 to 1.19
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.46 · 95% CI -3.27 to 2.36
SecondaryChange From Open-Label Baseline in Number of Joints With Active Arthritis at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-Label Phase Part 1

The ACR defined a joint with active arthritis as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by pain on motion, or tenderness.

Time frame:
Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 1 Day 7, Part 1 Weeks 2, 4, 8, 12 and 16
Reported as:
Mean · Joints
Change From Open-Label Baseline in Number of Joints With Active Arthritis at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-Label Phase Part 1
JointsTofacitinib 5mg BID OL Part 1
Part 1 Day 7-2.96 ± 4.17
Part 1 Week 2-4.21 ± 5.31
Part 1 Week 4-6.03 ± 6.04
Part 1 Week 8-7.80 ± 9.25
Part 1 Week 12-7.52 ± 7.38
Part 1 Week 16-6.38 ± 7.87
SecondaryChange From Open-Label Baseline in Number of Joints With Active Arthritis at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2

The ACR defined a joint with active arthritis as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by pain on motion, or tenderness.

Time frame:
Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 2 Weeks 4, 8, 12, 16, 20, 24
Reported as:
Mean · Joints
Change From Open-Label Baseline in Number of Joints With Active Arthritis at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2
JointsTofacitinib 5mg BID OL Part 2
Part 2 Week 4-7.78 ± 7.78
Part 2 Week 8-7.73 ± 8.40
Part 2 Week 12-9.26 ± 7.98
Part 2 Week 16-10.00 ± 7.99
Part 2 Week 20-10.85 ± 7.83
Part 2 Week 24-13.67 ± 11.02
SecondaryChange From Open-Label Baseline in Number of Joints With Limited Range of Motion at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-Label Phase Part 1

Limitation of motion were assessed in the following joints: Temporomandibular, shoulder, elbow, wrist, metacarpophalangeal (MCP I-V), proximal interphalangeal (PIP I-V), distal interphalangeal (II-V), hip, knee, ankle, subtalar joints, intertarsal joints, metatarsophalangeal (MTP I-V), toe interphalangeal (I-V), cervical spine, thoracic spine, lumbar spine.

Time frame:
Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 1 Day 7, Weeks 2, 4, 8, 12, 16
Reported as:
Mean · Joints
Change From Open-Label Baseline in Number of Joints With Limited Range of Motion at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-Label Phase Part 1
JointsTofacitinib 5mg BID OL Part 1
Part 1 Day 7-1.83 ± 4.26
Part 1 Week 2-2.06 ± 4.70
Part 1 Week 4-2.90 ± 5.42
Part 1 Week 8-4.36 ± 8.59
Part 1 Week 12-3.64 ± 6.05
Part 1 Week 16-2.33 ± 3.48
SecondaryChange From Open-Label Baseline in Number of Joints With Limited Range of Motion at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2

Limitation of motion were assessed in the following joints: Temporomandibular, shoulder, elbow, wrist, metacarpophalangeal (MCP I-V), proximal interphalangeal (PIP I-V), distal interphalangeal (II-V), hip, knee, ankle, subtalar joints, intertarsal joints, metatarsophalangeal (MTP I-V), Toe interphalangeal (I-V), cervical spine, thoracic spine, lumbar spine.

Time frame:
Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 2 Weeks 4, 8, 12, 16, 20, 24
Reported as:
Mean · Joints
Change From Open-Label Baseline in Number of Joints With Limited Range of Motion at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2
JointsTofacitinib 5mg BID OL Part 2
Part 2 Week 4-4.26 ± 6.75
Part 2 Week 8-3.90 ± 6.08
Part 2 Week 12-5.81 ± 7.48
Part 2 Week 16-5.74 ± 7.13
Part 2 Week 20-5.92 ± 9.32
Part 2 Week 24-15.67 ± 11.02
SecondaryChange From Open-Label Baseline in Physician Global Evaluation of Disease Activity at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-label Phase Part 1

Physician global evaluation of disease activity was assessed on a 21-numbered circle VAS ranging from 0 to 10, where 0= no disease activity and 10= maximum disease activity. Where higher scores indicated more disease activity.

Time frame:
Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 1 Day 7, Weeks 2, 4, 8, 12, 16
Reported as:
Mean · units on a scale
Change From Open-Label Baseline in Physician Global Evaluation of Disease Activity at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-label Phase Part 1
units on a scaleTofacitinib 5mg BID OL Part 1
Part 1 Day 7-1.18 ± 1.36
Part 1 Week 2-1.82 ± 1.68
Part 1 Week 4-2.62 ± 1.75
Part 1 Week 8-3.40 ± 2.01
Part 1 Week 12-3.66 ± 2.08
Part 1 Week 16-3.50 ± 1.93
SecondaryChange From Open-Label Baseline in Physician Global Evaluation of Disease Activity at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2

Physician global evaluation of disease activity was assessed on a 21-numbered circle VAS ranging from 0 to 10, where 0= no disease activity and 10= maximum disease activity. Where higher scores indicated more disease activity.

Time frame:
Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 2 Weeks 4, 8, 12, 16, 20, 24
Reported as:
Mean · Unit on a scale
Change From Open-Label Baseline in Physician Global Evaluation of Disease Activity at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2
Unit on a scaleTofacitinib 5mg BID OL Part 2
Part 2 Week 4-4.54 ± 2.10
Part 2 Week 8-4.53 ± 1.74
Part 2 Week 12-4.65 ± 1.57
Part 2 Week 16-4.89 ± 1.77
Part 2 Week 20-5.62 ± 1.21
Part 2 Week 24-6.17 ± 1.44
SecondaryChange From Open-Label Baseline in ESR at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-Label Phase Part 1

ESR was determined using an ESR testing kit.

Time frame:
Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 1 Day 7, Weeks 2, 4, 8, 12, 16
Reported as:
Mean · Millimeter per hour
Change From Open-Label Baseline in ESR at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-Label Phase Part 1
Millimeter per hourTofacitinib 5mg BID OL Part 1
Part 1 Day 7-11.00 ± 16.96
Part 1 Week 2-18.60 ± 19.78
Part 1 Week 4-24.70 ± 23.86
Part 1 Week 8-30.59 ± 23.12
Part 1 Week 12-31.74 ± 21.75
Part 1 Week 16-27.65 ± 28.84
SecondaryChange From Open-Label Baseline in ESR at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2

ESR was determined using an ESR testing kit.

Time frame:
Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 2 Weeks 4, 8, 12, 16, 20, 24
Reported as:
Mean · Millimeter per hour
Change From Open-Label Baseline in ESR at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2
Millimeter per hourTofacitinib 5mg BID OL Part 2
Part 2 Week 4-33.64 ± 28.16
Part 2 Week 8-30.73 ± 27.11
Part 2 Week 12-27.52 ± 28.13
Part 2 Week 16-23.48 ± 24.70
Part 2 Week 20-37.54 ± 20.93
Part 2 Week 24-24.33 ± 6.03
SecondaryChange From Open-Label Baseline in CHAQ- Parental Evaluation of Overall Well-being at Part 1 Days 3, 7, Part 1 Weeks 2, 4, 8, 12, 16: Open-Label Phase Part 1

The CHAQ, derived from the adult health assessment questionnaire, comprised of two indices disability and discomfort, and parent global assessment of overall well-being. For assessment of overall well-being, the parent/legal guardian/participant were required to rate the overall well-being by entering a number from 0 to 10 (in 0.5 increments), on a 21-circle VAS where '0= very well and 10=very poorly. Where higher scores indicated worse condition.

Time frame:
Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 1 Days 3,7, Part 1 Weeks 2, 4, 8, 12, 16
Reported as:
Mean · Units on a scale
Change From Open-Label Baseline in CHAQ- Parental Evaluation of Overall Well-being at Part 1 Days 3, 7, Part 1 Weeks 2, 4, 8, 12, 16: Open-Label Phase Part 1
Units on a scaleTofacitinib 5mg BID OL Part 1
Part 1 Day 3-0.73 ± 1.53
Part 1 Day 7-1.36 ± 1.91
Part 1 Week 2-1.96 ± 1.89
Part 1 Week 4-2.65 ± 2.44
Part 1 Week 8-3.35 ± 2.38
Part 1 Week 12-3.45 ± 2.45
Part 1 Week 16-3.48 ± 2.78
SecondaryChange From Open-Label Baseline in CHAQ - Parental Evaluation of Overall Well-being at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2

The CHAQ, derived from the adult health assessment questionnaire, comprised of two indices disability and discomfort, and parent global assessment of overall well-being. For assessment of overall well-being, the parent/legal guardian/participant were required to rate the overall well-being by entering a number from 0 to 10 (in 0.5 increments), on a 21-circle VAS where '0=Very Well and 10=Very Poorly. Where higher scores indicated worse condition.

Time frame:
Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 2 Weeks 4, 8, 12, 16, 20, 24
Reported as:
Mean · Units on a scale
Change From Open-Label Baseline in CHAQ - Parental Evaluation of Overall Well-being at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2
Units on a scaleTofacitinib 5mg BID OL Part 2
Part 2 Week 4-4.09 ± 2.68
Part 2 Week 8-4.50 ± 2.88
Part 2 Week 12-4.73 ± 2.83
Part 2 Week 16-5.11 ± 2.50
Part 2 Week 20-5.65 ± 2.89
Part 2 Week 24-6.33 ± 2.31
SecondaryChange From Open-Label Baseline in CHAQ - Disability Index at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-Label Phase Part 1

CHAQ, derived from the adult health assessment questionnaire, comprised of two indices disability and discomfort, and parent global assessment of overall Well-being. CHAQ disability index consisted of 30 items in 8 areas: 1. dressing and grooming, 2. arising, 3. eating, 4. walking, 5. hygiene, 6. reach, 7. grip, and 8. activities distributed. Each item was rated on a 4-point scale, scored from 0 (no difficulty) to 3 (unable to do). The eight areas of the CHAQ were averaged to calculate the total disability index score which ranged from 0 (no or minimal physical dysfunction) to 3 (very severe physical dysfunction), higher scores indicated more disability. A participant must have score for at least six of the eight areas, otherwise a CHAQ-DI score was not valid.

Time frame:
Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 1 Day 7, Weeks 2, 4, 8, 12, 16
Reported as:
Mean · Units on a scale
Change From Open-Label Baseline in CHAQ - Disability Index at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-Label Phase Part 1
Units on a scaleTofacitinib 5mg BID OL Part 1
Part 1 Day 7-0.21 ± 0.35
Part 1 Week 2-0.38 ± 0.43
Part 1 Week 4-0.52 ± 0.56
Part 1 Week 8-0.59 ± 0.57
Part 1 Week 12-0.51 ± 0.56
Part 1 Week 16-0.74 ± 0.73
SecondaryChange From Open-Label Baseline in CHAQ-Disability Index at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2

CHAQ, derived from the adult health assessment questionnaire, comprised of two indices disability and discomfort, and parent global assessment of overall well-being. CHAQ disability index consisted of 30 items in 8 areas, 1. dressing and grooming, 2. arising, 3. eating, 4. walking, 5. hygiene, 6. reach, 7. grip, and 8. activities distributed. Each item was rated on a 4-point scale, scored from 0 (no difficulty) to-3 (unable to do). The eight areas of the CHAQ were averaged to calculate the total disability index score which ranged from 0 (no or minimal physical dysfunction) to 3 (very severe physical dysfunction), higher scores indicated more disability. A participant must have score for at least six of the eight areas, otherwise a CHAQ-DI score was not valid.

Time frame:
Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 2 Weeks 4, 8, 12, 16, 20, 24
Reported as:
Mean · Units on a scale
Change From Open-Label Baseline in CHAQ-Disability Index at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2
Units on a scaleTofacitinib 5mg BID OL Part 2
Part 2 Week 4-0.79 ± 0.63
Part 2 Week 8-0.78 ± 0.76
Part 2 Week 12-0.85 ± 0.80
Part 2 Week 16-0.67 ± 0.74
Part 2 Week 20-0.93 ± 0.77
Part 2 Week 24-0.96 ± 0.92
SecondaryChange From Open-Label Baseline in Number of Joints With Active Arthritis at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase

The ACR defined a joint with active arthritis as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by pain on motion, or tenderness.

Time frame:
OL Baseline (last value collected prior to Day 1 of tofacitinib administration in OL phase), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Reported as:
Least squares mean · Joints
Change From Open-Label Baseline in Number of Joints With Active Arthritis at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase
JointsTofacitinib 5mg BID DBPlacebo DB
DB Week 4-6.53 ± 0.34-7.39 ± 0.32
DB Week 8-6.36 ± 0.38-7.69 ± 0.38
DB Week 12-5.92 ± 0.80-7.36 ± 0.76
DB Week 16-7.34 ± 0.25-7.37 ± 0.25
DB Week 20-7.41 ± 0.18-7.51 ± 0.20
DB Week 24-7.33 ± 0.13-7.76 ± 0.13
DB Week 28-6.36 ± 0.59-6.56 ± 0.67
DB Week 32-7.27 ± 0.17-7.76 ± 0.19
DB Week 36-7.43 ± 0.14-7.78 ± 0.16
DB Week 40-7.06 ± 0.24-7.58 ± 0.27
DB Week 44-7.39 ± 0.33-7.20 ± 0.35
DB Week 48-7.54 ± 0.20-7.75 ± 0.25
DB Week 52-7.46 ± 0.26-7.51 ± 0.28
Statistical analysis
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.86 · 95% CI -0.08 to 1.79
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 1.32 · 95% CI 0.25 to 2.40
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 1.43 · 95% CI -0.79 to 3.66
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.02 · 95% CI -0.70 to 0.74
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.11 · 95% CI -0.43 to 0.64
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.44 · 95% CI 0.06 to 0.81
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.21 · 95% CI -1.64 to 2.06
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.49 · 95% CI -0.04 to 1.03
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.35 · 95% CI -0.09 to 0.79
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.52 · 95% CI -0.23 to 1.28
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.19 · 95% CI -1.20 to 0.83
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.21 · 95% CI -0.49 to 0.91
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.06 · 95% CI -0.80 to 0.92
SecondaryChange From Double-Blind Baseline in Number of Joints With Active Arthritis at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase

The ACR defined a joint with active arthritis as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by pain on motion, or tenderness.

Time frame:
DB Baseline (randomization), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Reported as:
Least squares mean · Joints
Change From Double-Blind Baseline in Number of Joints With Active Arthritis at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase
JointsTofacitinib 5mg BID DBPlacebo DB
DB Week 40.38 ± 0.260.09 ± 0.24
DB Week 80.78 ± 0.38-0.23 ± 0.37
DB Week 121.47 ± 0.850.22 ± 0.81
DB Week 160.05 ± 0.27-0.05 ± 0.27
DB Week 20-0.15 ± 0.15-0.02 ± 0.17
DB Week 24-0.06 ± 0.12-0.39 ± 0.13
DB Week 280.71 ± 0.700.88 ± 0.84
DB Week 320.01 ± 0.18-0.41 ± 0.20
DB Week 36-0.14 ± 0.15-0.47 ± 0.17
DB Week 400.31 ± 0.25-0.37 ± 0.28
DB Week 44-0.05 ± 0.350.11 ± 0.38
DB Week 48-0.20 ± 0.21-0.56 ± 0.27
DB Week 52-0.14 ± 0.28-0.38 ± 0.34
Statistical analysis
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.29 · 95% CI -0.43 to 1.00
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 1.01 · 95% CI -0.06 to 2.08
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 1.25 · 95% CI -1.13 to 3.64
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.10 · 95% CI -0.68 to 0.88
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.13 · 95% CI -0.58 to 0.33
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.32 · 95% CI -0.03 to 0.68
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.17 · 95% CI -2.42 to 2.08
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.42 · 95% CI -0.14 to 0.97
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.32 · 95% CI -0.15 to 0.79
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.68 · 95% CI -0.14 to 1.49
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.16 · 95% CI -1.28 to 0.96
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.37 · 95% CI -0.43 to 1.16
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.24 · 95% CI -0.82 to 1.30
SecondaryChange From Open-Label Baseline in CHAQ-Disability Index at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase

The parents were asked to provide responses to questions designed to assessed function in 8 distributed, among a total of 30 items. Each question was rated on a four-point scale, scored from 0-3. The question with the highest score determined the score for the functional area. If aids or devices were used or assistance was required, the minimum score for that was 2. Each question was rated 0 for no difficulty, 1 for some difficulties, 2 for much difficulties, and 3 for unable to do. The 8 areas of the CHAQ were averaged to calculated disability index which was ranges from 0 (no or minimal physical dysfunction) to 3 (very severe physical dysfunction). A participant must have score for at least 6 of the 8 categories, otherwise a CHAQ-DI score was not valid.

Time frame:
OL Baseline (last value collected prior to Day 1 of tofacitinib administration in OL phase), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Reported as:
Least squares mean · Units on a scale
Change From Open-Label Baseline in CHAQ-Disability Index at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase
Units on a scaleTofacitinib 5mg BID DBPlacebo DB
DB Week 4-0.81 ± 0.10-1.03 ± 0.09
DB Week 8-0.93 ± 0.08-1.02 ± 0.08
DB Week 12-0.99 ± 0.08-1.04 ± 0.07
DB Week 16-0.95 ± 0.09-1.05 ± 0.09
DB Week 20-1.02 ± 0.07-1.21 ± 0.07
DB Week 24-0.94 ± 0.08-1.05 ± 0.08
DB Week 28-0.94 ± 0.08-1.01 ± 0.09
DB Week 32-0.96 ± 0.07-1.11 ± 0.07
DB Week 36-1.05 ± 0.08-1.16 ± 0.09
DB Week 40-1.07 ± 0.07-1.22 ± 0.08
DB Week 44-1.04 ± 0.09-1.08 ± 0.09
DB Week 48-1.01 ± 0.09-1.10 ± 0.11
DB Week 52-1.04 ± 0.10-1.13 ± 0.12
Statistical analysis
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.21 · 95% CI -0.07 to 0.50
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.09 · 95% CI -0.15 to 0.32
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.05 · 95% CI -0.17 to 0.28
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.10 · 95% CI -0.16 to 0.36
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.19 · 95% CI -0.01 to 0.38
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.12 · 95% CI -0.12 to 0.35
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.07 · 95% CI -0.18 to 0.31
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.15 · 95% CI -0.06 to 0.37
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.11 · 95% CI -0.14 to 0.36
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.16 · 95% CI -0.06 to 0.38
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.04 · 95% CI -0.22 to 0.30
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.09 · 95% CI -0.20 to 0.38
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.09 · 95% CI -0.24 to 0.42
SecondaryChange From Double Blind Baseline in CHAQ-Disability Index at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase

The parents were asked to provide responses to questions designed to assessed function in 8 distributed, among a total of 30 items. Each question was rated on a four-point scale, scored from 0-3. The question with the highest score determined the score for the functional area. If aids or devices were used or assistance was required, the minimum score for that was 2. Each question was rated 0 for no difficulty, 1 for some difficulties, 2 for much difficulties, and 3 for unable to do. The 8 areas of the CHAQ were averaged to calculated disability index which was ranges from 0 (no or minimal physical dysfunction) to 3 (very severe physical dysfunction). A participant must have score for at least 6 of the 8 categories, otherwise a CHAQ-DI score was not valid.

Time frame:
DB Baseline (randomization), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Reported as:
Least squares mean · Units on a scale
Change From Double Blind Baseline in CHAQ-Disability Index at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase
Units on a scaleTofacitinib 5mg BID DBPlacebo DB
DB Week 40.04 ± 0.06-0.02 ± 0.06
DB Week 8-0.03 ± 0.06-0.01 ± 0.06
DB Week 12-0.06 ± 0.06-0.05 ± 0.06
DB Week 16-0.03 ± 0.07-0.05 ± 0.07
DB Week 20-0.08 ± 0.06-0.23 ± 0.06
DB Week 240.06 ± 0.08-0.09 ± 0.08
DB Week 280.05 ± 0.08-0.04 ± 0.09
DB Week 320.02 ± 0.07-0.13 ± 0.07
DB Week 36-0.03 ± 0.09-0.19 ± 0.09
DB Week 40-0.09 ± 0.07-0.25 ± 0.07
DB Week 44-0.06 ± 0.09-0.10 ± 0.09
DB Week 48-0.03 ± 0.09-0.19 ± 0.12
DB Week 52-0.05 ± 0.10-0.21 ± 0.13
Statistical analysis
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.07 · 95% CI -0.10 to 0.24
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.02 · 95% CI -0.19 to 0.15
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.01 · 95% CI -0.19 to 0.16
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.01 · 95% CI -0.20 to 0.23
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.15 · 95% CI -0.02 to 0.32
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.15 · 95% CI -0.09 to 0.40
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.09 · 95% CI -0.16 to 0.34
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.15 · 95% CI -0.05 to 0.36
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.16 · 95% CI -0.10 to 0.43
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.17 · 95% CI -0.06 to 0.39
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.04 · 95% CI -0.22 to 0.30
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.15 · 95% CI -0.18 to 0.49
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.16 · 95% CI -0.23 to 0.55
SecondaryChange From Open-Label Baseline in Number of Joints With Limited Range of Motion at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase

Limitation of motion were assessed in the following joints: Temporomandibular, shoulder, elbow, wrist, metacarpophalangeal (MCP I-V), proximal interphalangeal (PIP I-V), distal interphalangeal (II-V), hip, knee, ankle, subtalar joints, intertarsal joints, metatarsophalangeal (MTP I-V), toe interphalangeal (I-V), cervical spine, thoracic spine, lumbar spine.

Time frame:
OL baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Reported as:
Least squares mean · Joints
Change From Open-Label Baseline in Number of Joints With Limited Range of Motion at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase
JointsTofacitinib 5mg BID DBPlacebo DB
DB Week 4-2.47 ± 0.43-2.69 ± 0.41
DB Week 8-2.31 ± 0.45-2.89 ± 0.44
DB Week 12-2.09 ± 0.71-3.29 ± 0.68
DB Week 16-2.76 ± 0.44-2.70 ± 0.43
DB Week 20-2.79 ± 0.19-3.05 ± 0.19
DB Week 24-2.98 ± 0.19-3.07 ± 0.19
DB Week 28-2.56 ± 0.54-2.10 ± 0.56
DB Week 32-2.89 ± 0.18-3.24 ± 0.19
DB Week 36-2.90 ± 0.19-3.21 ± 0.21
DB Week 40-2.96 ± 0.24-3.24 ± 0.25
DB Week 44-2.95 ± 0.25-3.24 ± 0.26
DB Week 48-3.03 ± 0.27-3.25 ± 0.30
DB Week 52-2.75 ± 0.36-3.20 ± 0.36
Statistical analysis
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.21 · 95% CI -0.97 to 1.40
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.58 · 95% CI -0.68 to 1.84
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 1.20 · 95% CI -0.77 to 3.16
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.06 · 95% CI -1.30 to 1.18
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.26 · 95% CI -0.29 to 0.82
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.09 · 95% CI -0.46 to 0.64
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.46 · 95% CI -2.05 to 1.13
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.35 · 95% CI -0.18 to 0.88
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.31 · 95% CI -0.26 to 0.88
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.28 · 95% CI -0.43 to 0.99
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.29 · 95% CI -0.45 to 1.03
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.22 · 95% CI -0.63 to 1.08
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.45 · 95% CI -0.66 to 1.57
SecondaryChange From Double-Blind Baseline in Number of Joints With Limited Range of Motion at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase

Limitation of motion were assessed in the following joints: Temporomandibular, shoulder, elbow, wrist, metacarpophalangeal (MCP I-V), proximal interphalangeal (PIP I-V), distal interphalangeal (II-V), hip, knee, ankle, subtalar joints, intertarsal joints, metatarsophalangeal (MTP I-V), toe interphalangeal (I-V), cervical spine, thoracic spine, lumbar spine.

Time frame:
DB Baseline (values at randomization), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Reported as:
Least squares mean · Joints
Change From Double-Blind Baseline in Number of Joints With Limited Range of Motion at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase
JointsTofacitinib 5mg BID DBPlacebo DB
DB Week 40.08 ± 0.220.21 ± 0.20
DB Week 80.45 ± 0.420.06 ± 0.42
DB Week 120.48 ± 0.44-0.23 ± 0.42
DB Week 16-0.30 ± 0.170.10 ± 0.17
DB Week 20-0.36 ± 0.10-0.19 ± 0.11
DB Week 24-0.53 ± 0.10-0.22 ± 0.11
DB Week 28-0.05 ± 0.401.05 ± 0.46
DB Week 32-0.41 ± 0.10-0.48 ± 0.12
DB Week 36-0.48 ± 0.09-0.46 ± 0.10
DB Week 40-0.48 ± 0.15-0.43 ± 0.17
DB Week 44-0.47 ± 0.16-0.43 ± 0.17
DB Week 48-0.50 ± 0.20-0.47 ± 0.24
DB Week 52-0.21 ± 0.31-0.42 ± 0.33
Statistical analysis
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.13 · 95% CI -0.73 to 0.47
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.39 · 95% CI -0.81 to 1.59
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.70 · 95% CI -0.54 to 1.95
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.40 · 95% CI -0.90 to 0.10
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.16 · 95% CI -0.46 to 0.13
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.32 · 95% CI -0.63 to -0.01
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -1.09 · 95% CI -2.34 to 0.15
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.07 · 95% CI -0.26 to 0.40
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.02 · 95% CI -0.30 to 0.26
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.05 · 95% CI -0.53 to 0.43
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.05 · 95% CI -0.56 to 0.46
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.03 · 95% CI -0.74 to 0.69
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.20 · 95% CI -0.91 to 1.32
SecondaryChange From Open-Label Baseline in Physician Global Evaluation of Disease Activity at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase

Physician global evaluation of disease activity was assessed on a 21-numbered circle VAS ranging from 0 to 10, where 0= no disease activity and 10=maximum disease activity, where higher scores indicated more disease activity.

Time frame:
OL label Baseline (last value collected prior to Day 1 of tofacitinib administration in OL phase), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Reported as:
Least squares mean · Units on a scale
Change From Open-Label Baseline in Physician Global Evaluation of Disease Activity at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase
Units on a scaleTofacitinib 5mg BID DBPlacebo DB
DB Week 4-4.22 ± 0.33-5.22 ± 0.32
DB Week 8-4.23 ± 0.32-5.55 ± 0.32
DB Week 12-4.89 ± 0.36-5.42 ± 0.34
DB Week 16-4.96 ± 0.32-5.22 ± 0.32
DB Week 20-5.32 ± 0.23-5.64 ± 0.24
DB Week 24-5.11 ± 0.22-5.66 ± 0.23
DB Week 28-5.06 ± 0.37-5.26 ± 0.40
DB Week 32-5.08 ± 0.26-5.71 ± 0.28
DB Week 36-5.55 ± 0.16-6.03 ± 0.18
DB Week 40-5.23 ± 0.30-5.88 ± 0.33
DB Week 44-5.65 ± 0.21-5.87 ± 0.22
DB Week 48-5.87 ± 0.18-6.14 ± 0.24
DB Week 52-5.86 ± 0.26-5.97 ± 0.33
Statistical analysis
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 1.01 · 95% CI 0.09 to 1.92
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 1.31 · 95% CI 0.40 to 2.22
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.53 · 95% CI -0.47 to 1.53
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.26 · 95% CI -0.63 to 1.16
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.32 · 95% CI -0.33 to 0.97
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.55 · 95% CI -0.10 to 1.20
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.20 · 95% CI -0.93 to 1.33
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.62 · 95% CI -0.17 to 1.42
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.48 · 95% CI -0.02 to 0.98
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.64 · 95% CI -0.30 to 1.58
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.23 · 95% CI -0.40 to 0.85
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.26 · 95% CI -0.36 to 0.88
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.11 · 95% CI -0.87 to 1.09
SecondaryChange From Double-Blind Baseline in Physician Global Evaluation of Disease Activity at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase

Physician global evaluation of disease activity was assessed on a 21-numbered circle VAS ranging from 0 to 10, where 0= no disease activity and 10=maximum disease activity, where higher scores indicated more disease activity.

Time frame:
DB label Baseline (last value collected prior to Day 1 of tofacitinib administration in OL phase), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Reported as:
Least squares mean · Units on a scale
Change From Double-Blind Baseline in Physician Global Evaluation of Disease Activity at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase
Units on a scaleTofacitinib 5mg BID DBPlacebo DB
DB Week 40.16 ± 0.250.21 ± 0.24
DB Week 80.45 ± 0.32-0.14 ± 0.32
DB Week 120.10 ± 0.40-0.02 ± 0.39
DB Week 16-0.11 ± 0.340.15 ± 0.34
DB Week 20-0.51 ± 0.22-0.35 ± 0.23
DB Week 24-0.32 ± 0.22-0.37 ± 0.22
DB Week 280.09 ± 0.430.19 ± 0.47
DB Week 32-0.11 ± 0.29-0.42 ± 0.32
DB Week 36-0.74 ± 0.17-0.92 ± 0.18
DB Week 40-0.17 ± 0.35-0.53 ± 0.37
DB Week 44-0.79 ± 0.21-0.70 ± 0.22
DB Week 48-1.03 ± 0.20-1.09 ± 0.29
DB Week 52-1.00 ± 0.27-0.92 ± 0.39
Statistical analysis
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.05 · 95% CI -0.77 to 0.67
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.58 · 95% CI -0.37 to 1.53
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.12 · 95% CI -1.06 to 1.30
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.26 · 95% CI -1.27 to 0.74
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.16 · 95% CI -0.83 to 0.52
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.05 · 95% CI -0.61 to 0.71
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.10 · 95% CI -1.45 to 1.25
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.31 · 95% CI -0.61 to 1.23
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.18 · 95% CI -0.34 to 0.71
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.36 · 95% CI -0.74 to 1.46
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.09 · 95% CI -0.75 to 0.56
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.06 · 95% CI -0.68 to 0.81
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.08 · 95% CI -1.10 to 0.94
SecondaryChange From Open-Label Baseline in ESR at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase

ESR was determined using an ESR testing kit.

Time frame:
OL Baseline (last value collected prior to Day 1 of tofacitinib administration in OL phase), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Reported as:
Least squares mean · Millimeter per hour (mm/h)
Change From Open-Label Baseline in ESR at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase
Millimeter per hour (mm/h)Tofacitinib 5mg BID DBPlacebo DB
DB Week 4-32.65 ± 4.72-31.19 ± 4.49
DB Week 8-36.55 ± 4.38-29.32 ± 4.29
DB Week 12-38.30 ± 4.50-31.69 ± 4.35
DB Week 16-39.52 ± 4.06-31.02 ± 4.06
DB Week 20-41.82 ± 2.22-37.86 ± 2.32
DB Week 24-42.25 ± 2.25-40.81 ± 2.33
DB Week 28-37.83 ± 4.07-33.51 ± 4.39
DB Week 32-37.90 ± 3.67-35.04 ± 3.91
DB Week 36-39.36 ± 4.49-28.41 ± 4.79
DB Week 40-39.98 ± 4.12-35.70 ± 4.31
DB Week 44-47.16 ± 2.28-38.84 ± 2.34
DB Week 48-47.16 ± 2.29-42.32 ± 2.72
DB Week 52-51.46 ± 1.08-50.12 ± 1.24
Statistical analysis
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -1.46 · 95% CI -14.59 to 11.66
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -7.22 · 95% CI -19.62 to 5.17
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -6.61 · 95% CI -19.36 to 6.14
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -8.50 · 95% CI -20.28 to 3.27
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -3.95 · 95% CI -10.53 to 2.62
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -1.44 · 95% CI -8.09 to 5.21
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -4.32 · 95% CI -16.67 to 8.03
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -2.86 · 95% CI -13.97 to 8.25
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -10.95 · 95% CI -24.63 to 2.73
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -4.28 · 95% CI -16.74 to 8.18
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -8.32 · 95% CI -15.20 to -1.43
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -4.84 · 95% CI -12.60 to 2.92
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -1.34 · 95% CI -5.16 to 2.48
SecondaryChange From Double-Blind Baseline in ESR at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase

ESR was determined using an ESR testing kit.

Time frame:
DB Baseline (values at randomization), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Reported as:
Least squares mean · Millimeter/ hour (mm/h)
Change From Double-Blind Baseline in ESR at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase
Millimeter/ hour (mm/h)Tofacitinib 5mg BID DBPlacebo DB
DB Week 43.35 ± 3.719.41 ± 3.50
DB Week 81.94 ± 3.9712.39 ± 3.93
DB Week 121.42 ± 4.5312.28 ± 4.40
DB Week 160.45 ± 4.3213.59 ± 4.35
DB Week 20-2.04 ± 2.174.98 ± 2.31
DB Week 24-2.51 ± 2.142.01 ± 2.28
DB Week 281.73 ± 4.1911.08 ± 4.55
DB Week 322.01 ± 3.788.77 ± 4.05
DB Week 360.88 ± 4.8316.37 ± 5.17
DB Week 400.34 ± 4.258.33 ± 4.47
DB Week 44-7.05 ± 2.343.44 ± 2.41
DB Week 48-8.07 ± 2.38-2.14 ± 2.96
DB Week 52-11.70 ± 1.39-9.14 ± 1.73
Statistical analysis
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -6.05 · 95% CI -16.30 to 4.19
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -10.46 · 95% CI -21.68 to 0.77
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -10.86 · 95% CI -23.75 to 2.03
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -13.15 · 95% CI -25.83 to -0.46
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -7.02 · 95% CI -13.56 to -0.47
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -4.53 · 95% CI -11.00 to 1.95
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -9.35 · 95% CI -22.24 to 3.54
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -6.75 · 95% CI -18.34 to 4.83
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -15.49 · 95% CI -30.36 to -0.63
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -7.99 · 95% CI -21.00 to 5.03
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -10.49 · 95% CI -17.67 to -3.31
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -5.93 · 95% CI -13.53 to 1.67
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -2.57 · 95% CI -6.37 to 1.24
SecondaryChange From Open-Label Baseline in CHAQ -Parental Evaluation of Overall Well-being at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase

The CHAQ, derived from the adult health assessment questionnaire, comprised of two indices disability and discomfort, and parent global assessment of overall well-being. For assessment of overall well-being, the parent/legal guardian/participant were required to rate the overall well-being by entering a number from 0 to 10 (in 0.5 increments), on a 21-circle VAS where '0'= very well' and '10= very poorly, where higher scores indicated worse condition.

Time frame:
OL label Baseline (last value collected prior to Day 1 of tofacitinib administration in OL phase), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Reported as:
Least squares mean · Units on a scale
Change From Open-Label Baseline in CHAQ -Parental Evaluation of Overall Well-being at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase
Units on a scaleTofacitinib 5mg BID DBPlacebo DB
DB Week 4-4.31 ± 0.37-5.52 ± 0.34
DB Week 8-4.56 ± 0.36-5.38 ± 0.35
DB Week 12-4.97 ± 0.34-5.28 ± 0.33
DB Week 16-4.88 ± 0.29-5.46 ± 0.29
DB Week 20-5.19 ± 0.32-5.36 ± 0.34
DB Week 24-4.97 ± 0.29-5.62 ± 0.30
DB Week 28-5.08 ± 0.44-5.00 ± 0.48
DB Week 32-5.63 ± 0.18-5.55 ± 0.20
DB Week 36-5.81 ± 0.18-5.87 ± 0.21
DB Week 40-5.98 ± 0.16-5.94 ± 0.18
DB Week 44-5.95 ± 0.21-5.79 ± 0.23
DB Week 48-5.45 ± 0.31-5.30 ± 0.57
DB Week 52-6.06 ± 0.25-5.98 ± 0.43
Statistical analysis
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.51 · 95% CI 0.20 to 2.22
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.82 · 95% CI -0.20 to 1.85
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.31 · 95% CI -0.65 to 1.27
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.57 · 95% CI -0.26 to 1.41
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.16 · 95% CI -0.78 to 1.10
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.66 · 95% CI -0.18 to 1.49
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.08 · 95% CI -1.43 to 1.27
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.07 · 95% CI -0.65 to 0.50
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.06 · 95% CI -0.51 to 0.63
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.04 · 95% CI -0.55 to 0.47
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.16 · 95% CI -0.82 to 0.50
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.14 · 95% CI -1.51 to 1.22
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.08 · 95% CI -1.05 to 0.88
SecondaryChange From Double-Blind Baseline in CHAQ -Parental Evaluation of Overall Well-being at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase

The CHAQ, derived from the adult health assessment questionnaire, comprised of two indices disability and discomfort, and parent global assessment of overall well-being. For assessment of overall well-being, the parent/legal guardian/participant were required to rate the overall well-being by entering a number from 0 to 10 (in 0.5 increments), on a 21-circle VAS where '0'= very well' and '10=very poorly.

Time frame:
DB Baseline (value at randomization), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Reported as:
Least squares mean · Units on a scale
Change From Double-Blind Baseline in CHAQ -Parental Evaluation of Overall Well-being at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase
Units on a scaleTofacitinib 5mg BID DBPlacebo DB
DB Week 40.46 ± 0.28-0.03 ± 0.27
DB Week 80.60 ± 0.380.12 ± 0.38
DB Week 120.25 ± 0.360.22 ± 0.35
DB Week 160.27 ± 0.310.04 ± 0.31
DB Week 200.14 ± 0.370.05 ± 0.38
DB Week 240.14 ± 0.29-0.14 ± 0.30
DB Week 280.54 ± 0.520.52 ± 0.56
DB Week 32-0.32 ± 0.24-0.34 ± 0.25
DB Week 36-0.56 ± 0.21-0.63 ± 0.22
DB Week 40-0.72 ± 0.19-0.78 ± 0.20
DB Week 44-0.65 ± 0.24-0.54 ± 0.25
DB Week 48-0.16 ± 0.36-0.37 ± 0.53
DB Week 52-0.82 ± 0.26-0.87 ± 0.38
Statistical analysis
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.49 · 95% CI -0.32 to 1.30
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.48 · 95% CI -0.64 to 1.61
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.03 · 95% CI -1.02 to 1.07
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.23 · 95% CI -0.69 to 1.14
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.09 · 95% CI -1.05 to 1.22
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.28 · 95% CI -0.60 to 1.16
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.02 · 95% CI -1.60 to 1.64
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.02 · 95% CI -1.60 to 1.64
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.07 · 95% CI -0.58 to 0.73
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.06 · 95% CI -0.53 to 0.65
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.12 · 95% CI -0.87 to 0.64
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.21 · 95% CI -1.13 to 1.54
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.05 · 95% CI -1.00 to 1.11
SecondaryChange From Open-Label Baseline in Child Health Questionnaire (CHQ) Responses at End of Open-Label Phase Part 1

The CHQ is a validated general pediatric quality of life instrument. The CHQ assessed for 14 physical and psychosocial domains: general health perceptions (global health perception), physical functioning, role/social physical functioning, bodily pain, role/social emotional functioning, role/social behavioral functioning, parent/legal guardian/adult caregiver impact-time, parent/legal guardian/adult caregiver impact-emotional, self-esteem, mental health, behavior, family activities, family cohesion, and change in health. The response options for the CHQ are ordinal scales that vary by the item. Each item consisted of 4-6 response options. The CHQ score was determined based on the parent/legal guardian/adult caregiver's questionnaire responses. Range on subscales and the overall scale is 0 to 100, where 0 is the worst possible health state and 100 the best possible health state.

Time frame:
OL Baseline up to 16 weeks
Reported as:
Mean · Units on a scale
Change From Open-Label Baseline in Child Health Questionnaire (CHQ) Responses at End of Open-Label Phase Part 1
Units on a scaleTofacitinib 5mg BID OL Part 1
Global Health Subscale Standardized Score26.12 ± 29.10
Physical Functioning Subscale Standardized Score28.95 ± 33.79
Social Limitations: Emotional Subscale Standardized Score27.51 ± 38.39
Social Limitations: Physical Subscale Standardized Score31.15 ± 42.96
Bodily Pain Subscale Standardized Score32.00 ± 26.67
Behavior Subscale Standardized Score10.98 ± 17.14
Global Behavior Subscale Standardized Score11.18 ± 27.75
Mental Health Subscale Standardized Score13.33 ± 20.20
Self Esteem Subscale Standardized Score7.68 ± 21.29
General Health Subscale Standardized Score8.37 ± 13.93
Change in Health Subscale Score1.28 ± 1.10
Emotional Impact on Parent Subscale Standardized Score12.75 ± 26.43
Time Impact on Parent Subscale Standardized Score14.81 ± 28.62
Family Activities Subscale Standardized Score74.03 ± 22.41
Family Cohesion Subscale Standardized Score8.10 ± 22.67
SecondaryChange From Open-Label Baseline in CHQ Responses at End of Open-Label Phase Part 2

The CHQ is a validated general pediatric quality of life instrument. The CHQ assessed for 14 physical and psychosocial domains: general health perceptions (global health perception), physical functioning, role/social physical functioning, bodily pain, role/social emotional functioning, role/social behavioral functioning, parent/legal guardian/adult caregiver impact-time, parent/legal guardian/adult caregiver impact-emotional, self-esteem, mental health, behavior, family activities, family cohesion, and change in health. The response options for the CHQ are ordinal scales that vary by the item. Each item consisted of 4-6 response options. The CHQ score was determined based on the parent/legal guardian/adult caregiver's questionnaire responses. Range on subscales and the overall scale is 0 to 100, where 0 is the worst possible health state and 100 the best possible health state.

Time frame:
Baseline (last value collected prior to Day 1 of tofacitinib administration in OL phase) up to 24 weeks
Reported as:
Mean · Units on a scale
Change From Open-Label Baseline in CHQ Responses at End of Open-Label Phase Part 2
Units on a scaleTofacitinib 5mg BID OL Part 2
Global Health Standardized Score25.52 ± 35.46
Physical Functioning Standardized Score33.33 ± 31.29
Social Limitations: Emotional Score28.17 ± 43.98
Social Limitations: Physical Score38.10 ± 42.28
Bodily Pain Standardized Score34.48 ± 26.80
Behavior Standardized Score13.02 ± 21.14
Global Behavior Standardized Score10.00 ± 34.10
Mental Health Standardized Score18.04 ± 21.01
Self Esteem Standardized Score8.30 ± 34.18
General Health Standardized Score8.18 ± 15.94
Change in Health Subscale Score1.54 ± 1.23
Emotional Impact on Parent Standardized Score22.92 ± 36.33
Time Impact on Parent Standardized Score34.57 ± 25.66
Family Activities Standardized Score27.62 ± 25.87
Family Cohesion Standardized Score10.00 ± 23.25
SecondaryChange From Double-Blind Baseline in CHQ Responses at DB Weeks 24, 48: Double-Blind Phase

The CHQ is a validated general pediatric quality of life instrument. The CHQ assessed for 14 physical and psychosocial domains: general health perceptions (global health perception), physical functioning, role/social physical functioning, bodily pain, role/social emotional functioning, role/social behavioral functioning, parent/legal guardian/adult caregiver impact-time, parent/legal guardian/adult caregiver impact-emotional, self-esteem, mental health, behavior, family activities, family cohesion, and change in health. The response options for the CHQ are ordinal scales that vary by the item. Each item consisted of 4-6 response options. The CHQ score was determined based on the parent/legal guardian/adult caregiver's questionnaire responses. Range on subscales and the overall scale is 0 to 100, where 0 is the worst possible health state and 100 the best possible health state.

Time frame:
DB Baseline (values at randomization), DB Weeks 24, 48
Reported as:
Least squares mean · Units on a scale
Change From Double-Blind Baseline in CHQ Responses at DB Weeks 24, 48: Double-Blind Phase
Units on a scaleTofacitinib 5mg BID DBPlacebo DB
CHQ01-Global Health Subscale Standardized Score: DB Week 244.02 ± 4.71-1.98 ± 5.02
CHQ01-Global Health Subscale Standardized Score: DB Week 484.09 ± 3.931.24 ± 4.49
CHQ01-Physical Functioning Subscale Standardized Score: DB Week 242.51 ± 3.866.70 ± 3.99
CHQ01-Physical Functioning Subscale Standardized Score: DB Week 485.24 ± 9.132.93 ± 14.02
CHQ01-Social Limitations: Emotional Subscale Standardized Score: DB Week 242.62 ± 4.008.09 ± 4.18
CHQ01-Social Limitations: Emotional Subscale Standardized Score: DB Week 486.09 ± 7.69-0.73 ± 10.33
CHQ01-Social Limitations: Physical Subscale Standardized Score: DB Week 242.75 ± 4.278.98 ± 4.54
CHQ01-Social Limitations: Physical Subscale Standardized Score: DB Week 483.45 ± 13.33-7.64 ± 20.06
CHQ01-Bodily Pain Subscale Standardized Score: DB Week 24-1.61 ± 4.19-0.16 ± 4.41
CHQ01-Bodily Pain Subscale Standardized Score: DB Week 48-2.72 ± 10.19-19.92 ± 13.98
CHQ01-Behavior Subscale Standardized Score: DB Week 242.33 ± 2.687.48 ± 2.87
CHQ01-Behavior Subscale Standardized Score: DB Week 48-4.50 ± 4.9710.53 ± 5.35
CHQ01-Global Behavior Subscale Standardized Score: DB Week 244.17 ± 3.899.48 ± 4.13
CHQ01-Global Behavior Subscale Standardized Score: DB Week 485.90 ± 4.0013.14 ± 4.54
CHQ01-Mental Health Subscale Standardized Score: DB Week 246.59 ± 3.562.14 ± 3.78
CHQ01-Mental Health Subscale Standardized Score: DB Week 480.79 ± 4.988.26 ± 5.71
CHQ01-Self Esteem Subscale Standardized Score: DB Week 246.68 ± 3.056.69 ± 3.24
CHQ01-Self Esteem Subscale Standardized Score: DB Week 483.05 ± 7.2410.64 ± 8.04
CHQ01-General Health Subscale Standardized Score: DB Week 245.02 ± 3.210.03 ± 3.42
CHQ01-General Health Subscale Standardized Score: DB Week 489.59 ± 5.2010.60 ± 5.92
CHQ01-Change in Health Subscale Score: DB Week 240.45 ± 0.120.48 ± 0.13
CHQ01-Change in Health Subscale Score: DB Week 480.64 ± 0.320.16 ± 0.35
CHQ01-Emotion al Impact on Parent Subscale Standardized Score: DB Week 2415.00 ± 4.2812.75 ± 4.53
CHQ01-Emotion al Impact on Parent Subscale Standardized Score: DB Week 487.15 ± 10.2532.22 ± 11.79
CHQ01-Time Impact on Parent Subscale Standardized Score: DB Week 247.53 ± 5.105.66 ± 5.25
CHQ01-Time Impact on Parent Subscale Standardized Score: DB Week 4811.60 ± 8.9420.79 ± 14.05
CHQ01-Family Activities Subscale Standardized Score: DB Week 245.71 ± 2.969.68 ± 3.13
CHQ01-Family Activities Subscale Standardized Score: DB Week 486.65 ± 5.7315.95 ± 7.16
CHQ01-Family Cohesion Subscale Standardized Score: DB Week 242.84 ± 3.716.36 ± 3.96
CHQ01-Family Cohesion Subscale Standardized Score: DB Week 48-12.24 ± 13.088.18 ± 15.58
Statistical analysis
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 6.00 · 95% CI -8.35 to 20.36
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 2.85 · 95% CI -12.43 to 18.14
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -4.19 · 95% CI -15.78 to 7.40
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 2.31 · 95% CI -37.06 to 41.68
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -5.47 · 95% CI -17.37 to 6.43
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 6.82 · 95% CI -20.92 to 34.57
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -6.22 · 95% CI -18.95 to 6.50
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 11.09 · 95% CI -46.24 to 68.42
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -1.45 · 95% CI -13.97 to 11.06
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 17.20 · 95% CI -28.01 to 62.41
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -5.15 · 95% CI -13.24 to 2.93
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -15.03 · 95% CI -33.12 to 3.06
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -5.32 · 95% CI -16.92 to 6.29
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -7.24 · 95% CI -20.35 to 5.87
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 4.44 · 95% CI -6.18 to 15.07
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -7.46 · 95% CI -24.37 to 9.45
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.01 · 95% CI -9.14 to 9.13
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -7.59 · 95% CI -33.87 to 18.70
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 4.98 · 95% CI -4.81 to 14.77
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -1.02 · 95% CI -20.31 to 18.28
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.03 · 95% CI -0.40 to 0.33
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.48 · 95% CI -0.68 to 1.65
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 2.25 · 95% CI -10.59 to 15.10
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -25.07 · 95% CI -60.96 to 10.82
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 1.87 · 95% CI -13.55 to 17.29
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -9.19 · 95% CI -48.91 to 30.53
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -3.97 · 95% CI -12.84 to 4.90
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -9.30 · 95% CI -32.35 to 13.75
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -3.52 · 95% CI -14.84 to 7.81
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -20.42 · 95% CI -79.03 to 38.18
SecondaryChange From Open-Label Baseline in CHAQ-Discomfort Index at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-Label Phase Part 1

For the assessment of discomfort, the parent/legal guardian or adult caregiver who interacted daily with the participant were required to rate the overall pain the participant had due to illness by entering a number from 0 to 10 (in 0.5 increments), with '0' as 'no pain' and '10' as 'very severe pain' on a 21-circle VAS, where higher scores indicated more severe pain.

Time frame:
Baseline (last value collected prior to Day 1 of tofacitinib administration in OL phase) Part 1 Day 7, Weeks 2, 4, 8, 12, 16
Reported as:
Mean · Units on a scale
Change From Open-Label Baseline in CHAQ-Discomfort Index at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-Label Phase Part 1
Units on a scaleTofacitinib 5mg BID OL Part 1
Part 1 Day 7-1.20 ± 1.77
Part 1 Week 2-1.87 ± 2.07
Part 1 Week 4-2.57 ± 2.14
Part 1 Week 8-3.30 ± 2.45
Part 1 Week 12-3.57 ± 2.50
Part 1 Week 16-3.69 ± 2.28
SecondaryChange From Open-label Baseline in CHAQ-Discomfort Index at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2

For the assessment of discomfort, the parent/legal guardian or adult caregiver who interacted daily with the participant were required to rate the overall pain the participant had due to illness by entering a number from 0 to 10 (in 0.5 increments), with '0' as 'no pain' and '10' as 'very severe pain' on a 21-circle VAS, where higher scores indicated more pain.

Time frame:
Baseline (last value collected prior to Day 1 of tofacitinib administration in OL phase) Part 2 Weeks 4, 8, 12, 16, 20, 24
Reported as:
Mean · Units on a scale
Change From Open-label Baseline in CHAQ-Discomfort Index at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2
Units on a scaleTofacitinib 5mg BID OL Part 2
Part 2 Week 4-4.23 ± 3.14
Part 2 Week 8-4.38 ± 2.95
Part 2 Week 12-4.42 ± 3.26
Part 2 Week 16-4.48 ± 2.88
Part 2 Week 20-5.15 ± 3.52
Part 2 Week 24-6.00 ± 1.73
SecondaryChange From Double-Blind Baseline in CHAQ-Discomfort Index at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase

For the assessment of discomfort, the parent/legal guardian or adult caregiver who interacted daily with the participant were required to rate the overall pain the participant had due to illness by entering a number from 0 to 10 (in 0.5 increments), with '0' as 'no pain' and '10' as 'very severe pain' on a 21-circle VAS, where higher scores indicated more severe pain.

Time frame:
DB Baseline (value at randomization), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Reported as:
Least squares mean · Units on a scale
Change From Double-Blind Baseline in CHAQ-Discomfort Index at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase
Units on a scaleTofacitinib 5mg BID DBPlacebo DB
DB Week 40.13 ± 0.280.37 ± 0.26
DB Week 80.56 ± 0.360.02 ± 0.35
DB Week 120.04 ± 0.340.09 ± 0.32
DB Week 160.44 ± 0.36-0.11 ± 0.35
DB Week 200.09 ± 0.40-0.14 ± 0.42
DB Week 240.07 ± 0.27-0.25 ± 0.28
DB Week 28-0.03 ± 0.470.39 ± 0.51
DB Week 32-0.31 ± 0.390.01 ± 0.42
DB Week 36-0.55 ± 0.34-0.24 ± 0.37
DB Week 40-0.76 ± 0.20-0.83 ± 0.21
DB Week 44-1.09 ± 0.23-0.79 ± 0.24
DB Week 48-0.19 ± 0.49-0.43 ± 0.79
DB Week 52-0.85 ± 0.21-0.76 ± 0.34
Statistical analysis
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.24 · 95% CI -1.02 to 0.54
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.54 · 95% CI -0.49 to 1.57
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.47 · 95% CI -1.01 to 0.90
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.55 · 95% CI -0.49 to 1.58
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.23 · 95% CI -0.98 to 1.45
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.32 · 95% CI -0.51 to 1.14
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.42 · 95% CI -1.87 to 1.03
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.33 · 95% CI -1.53 to 0.88
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.31 · 95% CI -1.36 to 0.74
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.07 · 95% CI -0.55 to 0.69
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.31 · 95% CI -1.01 to 0.39
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: 0.23 · 95% CI -1.45 to 1.92
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in ls mean: -0.09 · 95% CI -0.87 to 0.69
SecondaryPercentage of Participants With Minimum Disease Activity Calculated From JADAS-27 CRP Score at Part 1 Day 7, Weeks 2, 4, 8, 12 and 16: Open-Label Phase Part 1

JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score were determined based on four components: Physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 (very well) to 10 (very poor), CRP (value normalized to 0 to 10 scale, where higher scores indicated more inflammation) and number of joints with active disease (27 joint assessment ranging from 0 to 27, where higher scores indicated more disease activity). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57, where higher scores indicated more disease activity. For participants with polyarthritis (\>4 active joints) minimal disease activity was defined as a JADAS-27 CRP score of: \<= 3.8. For participants with oligoarthritis (\<= 4 active joints) minimal disease activity was defined as a JADAS-27 CRP score of \<=2.

Time frame:
Part 1 Day 7, Part 1 Weeks 2, 4, 8, 12 and 16
Reported as:
Number · Percentage of participants
Percentage of Participants With Minimum Disease Activity Calculated From JADAS-27 CRP Score at Part 1 Day 7, Weeks 2, 4, 8, 12 and 16: Open-Label Phase Part 1
Percentage of participantsTofacitinib 5mg BID OL Part 1
Part 1 Day 73.09 (0 to 6.54)
Part 1 Week 25.21 (0.76 to 9.65)
Part 1 Week 46.19 (1.39 to 10.98)
Part 1 Week 813.75 (6.20 to 21.30)
Part 1 Week 1213.64 (3.50 to 23.78)
Part 1 Week 1625.00 (7.68 to 42.32)
SecondaryPercentage of Participants With Minimum Disease Activity Calculated From JADAS-27 ESR Score at Part 1 Day 7, Weeks 2, 4, 8, 12 and 16: Open-label Phase Part 1

JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 ESR score were determined based on four components: Physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 (very well) to 10 (very poor), ESR (value normalized to 0 to 10 scale, where higher scores indicated more inflammation) and number of joints with active disease (27 joint assessment ranging from 0 to 27, where higher scores indicated more disease activity). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57, where higher scores indicated more disease activity. For participants with polyarthritis (\>4 active joints) minimal disease activity was defined as a JADAS-27 ESR score of: \<= 3.8. For participants with oligoarthritis (\<= 4 active joints) minimal disease activity was defined as a JADAS-27 ESR score of \<=2.

Time frame:
Part 1 Day 7, Weeks 2, 4, 8, 12 and 16
Reported as:
Number · Percentage of participants
Percentage of Participants With Minimum Disease Activity Calculated From JADAS-27 ESR Score at Part 1 Day 7, Weeks 2, 4, 8, 12 and 16: Open-label Phase Part 1
Percentage of participantsTofacitinib 5mg BID OL Part 1
Part 1 Day 71.02 (0 to 3.01)
Part 1 Week 24.08 (0.16 to 8.00)
Part 1 Week 47.22 (2.07 to 12.37)
Part 1 Week 814.81 (7.08 to 22.55)
Part 1 Week 1215.91 (5.10 to 26.72)
Part 1 Week 1620.83 (4.59 to 37.08)
SecondaryPercentage of Participants With Minimum Disease Activity Calculated From JADAS-27 CRP Score at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2

JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score were determined based on four components: Physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 (very well) to 10 (very poor), CRP (value normalized to 0 to 10 scale, where higher scores indicated more inflammation) and number of joints with active disease (27 joint assessment ranging from 0 to 27, where higher scores indicated more disease activity). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57, where higher scores indicated more disease activity. For participants with polyarthritis (\>4 active joints) minimal disease activity was defined as a JADAS-27 CRP score of: \<= 3.8. For participants with oligoarthritis (\<= 4 active joints) minimal disease activity was defined as a JADAS-27 CRP score of \<=2.

Time frame:
Part 2 Weeks 4, 8, 12, 16, 20, 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Minimum Disease Activity Calculated From JADAS-27 CRP Score at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2
Percentage of participantsTofacitinib 5mg BID OL Part 2
Part 2 Week 436.00 (22.70 to 49.30)
Part 2 Week 830.00 (15.80 to 44.20)
Part 2 Week 1232.26 (15.80 to 48.71)
Part 2 Week 1636.36 (16.26 to 56.47)
Part 2 Week 2053.85 (26.75 to 80.95)
Part 2 Week 2433.33 (0 to 86.68)
SecondaryPercentage of Participants With Minimum Disease Activity Calculated From JADAS-27 ESR Score at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2

JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 ESR score were determined based on four components: Physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 (very well) to 10 (very poor), ESR (value normalized to 0 to 10 scale, where higher scores indicated more inflammation) and number of joints with active disease (27 joint assessment ranging from 0 to 27, where higher scores indicated more disease activity). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57, where higher scores indicated more disease activity. For participants with polyarthritis (\>4 active joints) minimal disease activity was defined as a JADAS-27 ESR score of: \<= 3.8. For participants with oligoarthritis (\<= 4 active joints) minimal disease activity was defined as a JADAS-27 ESR score of \<=2.

Time frame:
Part 2 Weeks 4, 8, 12, 16, 20, 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Minimum Disease Activity Calculated From JADAS-27 ESR Score at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2
Percentage of participantsTofacitinib 5mg BID OL Part 2
Part 2 Week 432.00 (19.07 to 44.93)
Part 2 Week 827.50 (13.66 to 41.34)
Part 2 Week 1229.03 (13.05 to 45.01)
Part 2 Week 1634.78 (15.32 to 54.25)
Part 2 Week 2053.85 (26.75 to 80.95)
Part 2 Week 2433.33 (0 to 86.68)
SecondaryPercentage of Participants With Inactive Disease Status Calculated From JADAS-27 CRP Score at Part 1 Day 7, Weeks 2, 4, 8, 12 and 16: Open-label Phase Part 1

JADAS-27 is a validated composite disease activity measure for JIA. Score were determined based on four components:Physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 (very well) to 10 (very poor), CRP (value normalized to 0 to 10 scale, where higher scores:more inflammation) and number of joints with active disease (27 joint assessment ranging from 0 to 27,where higher scores:more disease activity). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57,where higher scores:more disease activity.Inactive disease activity based on JADAS-27 CRP score was defined as: For participants with polyarthritis (\>4 active joints) inactive disease activity was defined as a JADAS-27 CRP score of:\<=1.For participants with oligoarthritis (\<=4 active joints) inactive disease activity was defined as a JADAS-27 CRP score of \<=1.

Time frame:
Part 1 Day 7, Weeks 2, 4, 8, 12 and 16
Reported as:
Number · Percentage of Participants
Percentage of Participants With Inactive Disease Status Calculated From JADAS-27 CRP Score at Part 1 Day 7, Weeks 2, 4, 8, 12 and 16: Open-label Phase Part 1
Percentage of ParticipantsTofacitinib 5mg BID OL Part 1
Part 1 Day 70 (0 to 0)
Part 1 Week 23.13 (0 to 6.61)
Part 1 Week 43.09 (0 to 6.54)
Part 1 Week 85.00 (0.22 to 9.78)
Part 1 Week 124.55 (0 to 10.70)
Part 1 Week 164.17 (0 to 12.16)
SecondaryPercentage of Participants With Inactive Disease Status Calculated From JADAS-27 ESR Score at Part 1 Day 7, Weeks 2, 4, 8, 12 and 16: Open-Label Phase Part 1

JADAS-27 is a validated composite disease activity measure for JIA. Score were determined based on four components:physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity);parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 (very well) to 10 (very poor), ESR (value normalized to 0 to 10 scale, where higher scores:more inflammation and number of joints with active disease (27 joint assessment ranging from 0 to 27, where higher scores:more disease activity). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57, where higher scores:more disease activity. Inactive Disease activity based on JADAS-27 ESR score was defined as for participants with polyarthritis(\>4 active joints) inactive disease activity was defined as a JADAS-27 ESR score of:\<=1. For participants with oligoarthritis (\<=4 active joints) inactive disease activity was defined as a JADAS-27 ESR score of \<=1.

Time frame:
Part 1 Day 7, Weeks 2, 4, 8, 12 and 16
Reported as:
Number · Percentage of Participants
Percentage of Participants With Inactive Disease Status Calculated From JADAS-27 ESR Score at Part 1 Day 7, Weeks 2, 4, 8, 12 and 16: Open-Label Phase Part 1
Percentage of ParticipantsTofacitinib 5mg BID OL Part 1
Part 1 Day 70 (0 to 0)
Part 1 Week 22.04 (0 to 4.84)
Part 1 Week 41.03 (0 to 3.04)
Part 1 Week 83.70 (0 to 7.82)
Part 1 Week 126.82 (0 to 14.27)
Part 1 Week 164.17 (0 to 12.16)
SecondaryPercentage of Participants With Inactive Disease Status Calculated From JADAS-27 CRP Score at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2

JADAS-27 is a validated composite disease activity measure for JIA.Score were determined based on four components:physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity);parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 (very well) to 10 (very poor), CRP (value normalized to 0 to 10 scale, where higher scores: more inflammation) and number of joints with active disease (27 joint assessment ranging from 0 to 27,where higher scores:more disease activity). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57,where higher scores: more disease activity.Inactive disease activity based on JADAS-27 CRP score was defined as: For participants with polyarthritis (\>4 active joints) inactive disease activity was defined as a JADAS-27 CRP score of:\<=1.For participants with oligoarthritis (\<=4 active joints) inactive disease activity was defined as a JADAS-27 CRP score of \<=1.

Time frame:
Part 2 Weeks 4, 8, 12, 16, 20, 24
Reported as:
Number · Percentage of Participants
Percentage of Participants With Inactive Disease Status Calculated From JADAS-27 CRP Score at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2
Percentage of ParticipantsTofacitinib 5mg BID OL Part 2
Part 2 Week 416.00 (5.84 to 26.16)
Part 2 Week 820.00 (7.60 to 32.40)
Part 2 Week 129.68 (0 to 20.09)
Part 2 Week 1618.18 (2.06 to 34.30)
Part 2 Week 2038.46 (12.01 to 64.91)
Part 2 Week 2433.33 (0 to 86.68)
SecondaryPercentage of Participants With Inactive Disease Status Calculated From JADAS-27 ESR Score at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2

JADAS-27 is a validated composite disease activity measure for JIA. Score were determined based on four components:physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity);parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 (very well) to 10 (very poor), ESR (value normalized to 0 to 10 scale, where higher scores:more inflammation and number of joints with active disease (27 joint assessment ranging from 0 to 27, where higher scores:more disease activity). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57, where higher scores:more disease activity. Inactive Disease activity based on JADAS-27 ESR score was defined as for participants with polyarthritis(\>4 active joints) inactive disease activity was defined as a JADAS-27 ESR score of:\<=1. For participants with oligoarthritis (\<=4 active joints) inactive disease activity was defined as a JADAS-27 ESR score of \<=1.

Time frame:
Part 2 Weeks 4, 8, 12, 16, 20, 24
Reported as:
Number · Percentage of Participants
Percentage of Participants With Inactive Disease Status Calculated From JADAS-27 ESR Score at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2
Percentage of ParticipantsTofacitinib 5mg BID OL Part 2
Part 2 Week 416.00 (5.84 to 26.16)
Part 2 Week 817.50 (5.72 to 29.28)
Part 2 Week 129.68 (0 to 20.09)
Part 2 Week 1617.39 (1.90 to 32.88)
Part 2 Week 2046.15 (19.05 to 73.25)
Part 2 Week 2433.33 (0 to 86.68)
SecondaryPercentage of Participants With Minimum Disease Activity Calculated From JADAS-27 CRP Score at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase

JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score were determined based on four components: Physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 (very well) to 10 (very poor), CRP (value normalized to 0 to 10 scale, where higher scores indicated more inflammation) and number of joints with active disease (27 joint assessment ranging from 0 to 27, where higher scores indicated more disease activity). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57, where higher scores indicated more disease activity. For participants with polyarthritis (\>4 active joints) minimal disease activity was defined as a JADAS-27 CRP score of: \<= 3.8. For participants with oligoarthritis (\<= 4 active joints) minimal disease activity was defined as a JADAS-27 CRP score of \<=2.

Time frame:
DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Reported as:
Number · Percentage of Participants
Percentage of Participants With Minimum Disease Activity Calculated From JADAS-27 CRP Score at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase
Percentage of ParticipantsTofacitinib 5mg BID DBPlacebo DB
DB Week 421.4351.61
DB Week 825.0048.39
DB Week 1232.1432.26
DB Week 1635.7129.03
DB Week 2035.7122.58
DB Week 2435.7135.48
DB Week 2835.7132.26
DB Week 3228.5722.58
DB Week 3639.2935.48
DB Week 4039.2929.03
DB Week 4446.4325.81
DB Week 4846.4325.81
DB Week 5246.4329.03
Statistical analysis
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -30.18 · 95% CI -53.43 to -6.94The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -23.39 · 95% CI -47.19 to 0.42The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -0.12 · 95% CI -23.99 to 23.76The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 6.68 · 95% CI -17.20 to 30.56The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 13.13 · 95% CI -9.92 to 36.19The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 0.23 · 95% CI -24.24 to 24.70The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 3.46 · 95% CI -20.75 to 27.66The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 5.99 · 95% CI -16.29 to 28.28The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 3.80 · 95% CI -20.92 to 28.52The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 10.25 · 95% CI -13.88 to 34.39The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 20.62 · 95% CI -3.43 to 44.67The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 20.62 · 95% CI -3.43 to 44.67The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 17.40 · 95% CI -7.03 to 41.82The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
SecondaryPercentage of Participants With Minimum Disease Activity Calculated From JADAS-27 ESR Score at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase

JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 ESR score were determined based on four components: Physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 (very well) to 10 (very poor), ESR (value normalized to 0 to 10 scale, where higher scores indicated more inflammation) and number of joints with active disease (27 joint assessment ranging from 0 to 27, where higher scores indicated more disease activity). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57, where higher scores indicated more disease activity. For participants with polyarthritis (\>4 active joints) minimal disease activity was defined as a JADAS-27 ESR score of: \<= 3.8. For participants with oligoarthritis (\<= 4 active joints) minimal disease activity was defined as a JADAS-27 ESR score of \<=2.

Time frame:
DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Reported as:
Number · Percentage of Participants
Percentage of Participants With Minimum Disease Activity Calculated From JADAS-27 ESR Score at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase
Percentage of ParticipantsTofacitinib 5mg BID DBPlacebo DB
DB Week 425.0051.61
DB Week 825.0045.16
DB Week 1232.1441.94
DB Week 1635.7135.48
DB Week 2039.2929.03
DB Week 2435.7138.71
DB Week 2835.7138.71
DB Week 3228.5735.48
DB Week 3639.2935.48
DB Week 4039.2932.26
DB Week 4450.0032.26
DB Week 4850.0035.48
DB Week 5250.0032.26
Statistical analysis
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -26.61 · 95% CI -50.42 to -2.81The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -20.16 · 95% CI -43.91 to 3.59The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -9.79 · 95% CI -34.31 to 14.72The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 0.23 · 95% CI -24.24 to 24.70The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 10.25 · 95% CI -13.88 to 34.39The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -3.00 · 95% CI -27.67 to 21.68The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -3.00 · 95% CI -27.67 to 21.68The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -6.91 · 95% CI -30.65 to 16.83The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 3.80 · 95% CI -20.92 to 28.52The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 7.03 · 95% CI -17.43 to 31.48The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 17.74 · 95% CI -7.03 to 42.52The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 14.52 · 95% CI -10.52 to 39.55The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 17.74 · 95% CI -7.03 to 42.52The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
SecondaryPercentage of Participants With Inactive Disease Status Calculated From JADAS-27 CRP Score at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase

JADAS-27 is a validated composite disease activity measure for JIA.Score were determined based on four components:physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 (very well) to 10 (very poor),CRP (value normalized to 0 to 10 scale, where higher scores:more inflammation) and number of joints with active disease (27 joint assessment ranging from 0 to 27, where higher scores:more disease activity).The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57, where higher scores:more disease activity. Inactive disease activity based on JADAS-27 CRP score was defined as: For participants with polyarthritis (\>4 active joints) inactive disease activity was defined as a JADAS-27 CRP score of:\<=1.For participants with oligoarthritis (\<=4 active joints) inactive disease activity was defined as a JADAS-27 CRP score of \<=1.

Time frame:
DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Reported as:
Number · Percentage of Participants
Percentage of Participants With Inactive Disease Status Calculated From JADAS-27 CRP Score at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase
Percentage of ParticipantsTofacitinib 5mg BID DBPlacebo DB
DB Week 410.7125.81
DB Week 87.1419.35
DB Week 127.1416.13
DB Week 1614.299.68
DB Week 2014.299.68
DB Week 247.1416.13
DB Week 2810.7122.58
DB Week 3214.2919.35
DB Week 3610.7116.13
DB Week 4014.2925.81
DB Week 4414.2916.13
DB Week 4810.7119.35
DB Week 5214.2919.35
Statistical analysis
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -15.09 · 95% CI -34.29 to 4.10The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -12.21 · 95% CI -29.08 to 4.65The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -8.99 · 95% CI -25.07 to 7.10The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 4.61 · 95% CI -12.01 to 21.23The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 4.61 · 95% CI -12.01 to 21.23The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -8.99 · 95% CI -25.07 to 7.10The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -11.87 · 95% CI -30.52 to 6.79The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -5.07 · 95% CI -24.08 to 13.94The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -5.41 · 95% CI -22.70 to 11.87The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -11.52 · 95% CI -31.65 to 8.61The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -1.84 · 95% CI -20.16 to 16.48The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -8.64 · 95% CI -26.66 to 9.38The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -5.07 · 95% CI -24.08 to 13.94The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
SecondaryPercentage of Participants With Inactive Disease Status Calculated From JADAS-27 ESR Score at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase

JADAS-27 is a validated composite disease activity measure for JIA. Score were determined based on four components:physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity);parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 (very well) to 10 (very poor), ESR (value normalized to 0 to 10 scale, where higher scores:more inflammation and number of joints with active disease (27 joint assessment ranging from 0 to 27, where higher scores:more disease activity). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57, where higher scores:more disease activity. Inactive Disease activity based on JADAS-27 ESR score was defined as for participants with polyarthritis(\>4 active joints) inactive disease activity was defined as a JADAS-27 ESR score of:\<=1. For participants with oligoarthritis (\<=4 active joints) inactive disease activity was defined as a JADAS-27 ESR score of \<=1.

Time frame:
DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Reported as:
Number · Percentage of Participants
Percentage of Participants With Inactive Disease Status Calculated From JADAS-27 ESR Score at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase
Percentage of ParticipantsTofacitinib 5mg BID DBPlacebo DB
DB Week 47.1419.35
DB Week 814.2929.03
DB Week 1214.2922.58
DB Week 1617.8616.13
DB Week 2014.2912.90
DB Week 2410.7116.13
DB Week 2810.7122.58
DB Week 3214.2919.35
DB Week 3610.7119.35
DB Week 4014.2925.81
DB Week 4414.2922.58
DB Week 4814.2922.58
DB Week 5214.2919.35
Statistical analysis
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -12.21 · 95% CI -29.08 to 4.65The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -14.75 · 95% CI -35.32 to 5.83The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -8.29 · 95% CI -27.91 to 11.32The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 1.73 · 95% CI -17.48 to 20.93The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 1.38 · 95% CI -16.15 to 18.91The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -5.41 · 95% CI -22.70 to 11.87The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -11.87 · 95% CI -30.52 to 6.79The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -5.07 · 95% CI -24.08 to 13.94The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -8.64 · 95% CI -26.66 to 9.38The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -11.52 · 95% CI -31.65 to 8.61The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -8.29 · 95% CI -27.91 to 11.32The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -8.29 · 95% CI -27.91 to 11.32The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -5.07 · 95% CI -24.08 to 13.94The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
SecondaryPercentage of Participants With JIA ACR Inactive Disease Status at Part 1 Days 3, 7, Weeks 2, 4, 8, 12, 16: Open-Label Phase Part 1

The ACR clinical inactive disease was defined as follows: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to sJIA; no active uveitis; normal ESR (within normal limits of the method used where tested) or, if elevated, not attributable to JIA; physician global assessment of disease activity score of 'best possible' on the 21-numbered circle VAS scale used (VAS from 0 to 10), higher scores indicated more disease activity; duration of morning stiffness of \<=15 minutes. 95% CI was based on normal approximation.

Time frame:
Baseline (last value collected prior to Day 1 of tofacitinib administration in OL phase) Part 1 Days 3, 7, Weeks 2, 4, 8, 12, 16
Reported as:
Number · Percentage of Participants
Percentage of Participants With JIA ACR Inactive Disease Status at Part 1 Days 3, 7, Weeks 2, 4, 8, 12, 16: Open-Label Phase Part 1
Percentage of ParticipantsTofacitinib 5mg BID OL Part 1
Baseline0 (0 to 0)
Part 1 Day 30 (0 to 0)
Part 1 Day 70 (0 to 0)
Part 1 Week 22.02 (0 to 4.79)
Part 1 Week 43.09 (0 to 6.54)
Part 1 Week 84.82 (0.21 to 9.43)
Part 1 Week 124.55 (0 to 10.70)
Part 1 Week 164.17 (0 to 12.16)
SecondaryPercentage of Participants With JIA ACR Inactive Disease Status at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2

The ACR clinical inactive disease was defined as follows: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to sJIA; no active uveitis; normal ESR (within normal limits of the method used where tested) or, if elevated, not attributable to JIA; physician global assessment of disease activity score of 'best possible' on the 21-numbered circle VAS scale used (VAS from 0 to 10), higher scores indicated more disease activity; duration of morning stiffness of \<=15 minutes. 95% CI was based on normal approximation. 95% CI was based on normal approximation.

Time frame:
Part 2 Weeks 4, 8, 12, 16, 20, 24
Reported as:
Number · Percentage of participants
Percentage of Participants With JIA ACR Inactive Disease Status at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2
Percentage of participantsTofacitinib 5mg BID OL Part 2
Part 2 Week 414.00 (4.38 to 23.62)
Part 2 Week 810.26 (0.73 to 19.78)
Part 2 Week 126.45 (0 to 15.10)
Part 2 Week 1613.04 (0 to 26.81)
Part 2 Week 2015.38 (0 to 35.00)
Part 2 Week 2433.33 (0 to 86.68)
SecondaryPercentage of Participants With JIA ACR Inactive Disease Status at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase

The ACR clinical inactive disease was defined as follows: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to sJIA; no active uveitis; normal ESR (within normal limits of the method used where tested) or, if elevated, not attributable to JIA; physician global assessment of disease activity score of 'best possible' on the 21-numbered circle VAS scale used (VAS from 0 to 10), higher scores indicated more disease activity; duration of morning stiffness of \<=15 minutes. 95% CI was based on normal approximation. 95% CI was based on normal approximation.

Time frame:
DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Reported as:
Number · Percentage of Participants
Percentage of Participants With JIA ACR Inactive Disease Status at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase
Percentage of ParticipantsTofacitinib 5mg BID DBPlacebo DB
DB Week 47.1416.13
DB Week 83.5722.58
DB Week 127.1422.58
DB Week 163.5716.13
DB Week 207.1416.13
DB Week 247.1419.35
DB Week 2810.7119.35
DB Week 3210.7119.35
DB Week 3614.2916.13
DB Week 4017.8622.58
DB Week 4414.2922.58
DB Week 4817.8622.58
DB Week 5221.4319.35
Statistical analysis
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -8.99 · 95% CI -25.07 to 7.10The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -19.01 · 95% CI -35.25 to -2.76The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -15.44 · 95% CI -32.98 to 2.10The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -12.56 · 95% CI -27.22 to 2.10The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -8.99 · 95% CI -25.07 to 7.10The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -12.21 · 95% CI -29.08 to 4.65The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -8.64 · 95% CI -26.66 to 9.38The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -8.64 · 95% CI -26.66 to 9.38The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -1.84 · 95% CI -20.16 to 16.48The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -4.72 · 95% CI -25.17 to 15.72The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -8.29 · 95% CI -27.91 to 11.32The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: -4.72 · 95% CI -25.17 to 15.72The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.
  • Tofacitinib 5mg BID DB vs Placebo DB · Difference in percentage: 2.07 · 95% CI -18.53 to 22.68The normal approximation to the difference in binomial proportions was used to generate 95% CI for the difference in percentage.

Adverse events

Collected over From dose 1 up to 28 days after end of study treatment (for OL1=maximum duration up to 16 weeks; for OL2= maximum duration up to 24 weeks and for DB=maximum duration up to 248 weeks). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tofacitinib 5mg BID OL Part 10/100 (0%)7/100 (7%)33/100 (33%)
Tofacitinib 5mg BID OL Part 20/54 (0%)0/54 (0%)15/54 (27.8%)
Tofacitinib 5mg BID DB0/28 (0%)0/28 (0%)23/28 (82.1%)
Placebo DB0/31 (0%)2/31 (6.5%)25/31 (80.6%)
Most frequent serious events
Most frequent serious events
EventTofacitinib 5mg BID OL Part 1Tofacitinib 5mg BID OL Part 2Tofacitinib 5mg BID DBPlacebo DB
NephrolithiasisRenal and urinary disorders0/1000/540/281/31
BronchitisInfections and infestations0/1000/540/281/31
Still's diseaseMusculoskeletal and connective tissue disorders3/1000/540/280/31
OverdoseInjury, poisoning and procedural complications1/1000/540/280/31
Histiocytic necrotising lymphadenitisNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1000/540/280/31
Hodgkin's diseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1000/540/280/31
Haemophagocytic lymphohistiocytosisImmune system disorders1/1000/540/280/31
DepressionPsychiatric disorders1/1000/540/280/31
Most frequent other events
Showing 10 of 81
Most frequent other events
EventTofacitinib 5mg BID OL Part 1Tofacitinib 5mg BID OL Part 2Tofacitinib 5mg BID DBPlacebo DB
Still's diseaseMusculoskeletal and connective tissue disorders0/1003/548/2814/31
Upper respiratory tract infectionInfections and infestations10/1007/543/285/31
PyrexiaGeneral disorders6/1002/544/281/31
VomitingGastrointestinal disorders3/1000/543/281/31
Urinary tract infectionInfections and infestations3/1000/540/283/31
COVID-19Infections and infestations0/1005/540/282/31
NasopharyngitisInfections and infestations6/1000/542/281/31
Haemoglobin decreasedInvestigations0/1000/542/280/31
HypertriglyceridaemiaMetabolism and nutrition disorders0/1000/542/280/31
FallInjury, poisoning and procedural complications0/1000/542/280/31

Baseline characteristics

Age, Customized
Age, Customized(Participants)Overall
2 to less than (<) 6 Years17
6 to < 12 Years43
12 to < 18 Years40
Sex: Female, Male
Sex: Female, Male(Participants)Overall
Female44
Male56
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Overall
Race — White39
Race — Black or African American7
Race — Asian49
Race — Other5
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Overall
Ethnicity — Hispanic or Latino14
Ethnicity — Not Hispanic or Latino86
08

Study locations

52 sites
  • Phoenix Children's Hospital
    Phoenix, Arizona 85016, United States
  • Children's Hospital Los Angeles
    Los Angeles, California 90027, United States
  • Ann & Robert H Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • Cohen Children's Medical Center of New York
    Lake Success, New York 11042, United States
  • Cohen Children's Medical Center of New York
    New Hyde Park, New York 11040, United States
  • Instituto CAICI SRL
    Rosario, Santa FE S2000PBJ, Argentina
  • Centro Medico Privado de Reumatologia
    San Miguel de Tucuman, Tucuman T4000AXL, Argentina
  • Universitair Ziekenhuis Gent
    Gent, 9000, Belgium
  • UPECLIN Unidade de Pesquisa Clinica da Faculdade de Medicina da UNESP
    Botucatu, SAO Paulo 18618-970, Brazil
  • Faculdade de Medicina da UNESP
    Botucatu, SÃO Paulo 18618-686, Brazil
  • SPDM - Associacao Paulista para o Desenvolvimento da Medicina
    Sao Paulo, 04024-002, Brazil
  • SPDM - Associacao Paulista para o Desenvolvimento da Medicina
    Sao Paulo, 04037-002, Brazil
  • Instituto da Crianca do Hospital das Clinicas da FMUSP
    Sao Paulo, 05409-011, Brazil
  • Alberta Children's Hospital/University of Calgary
    Calgary, Alberta T3B 6A8, Canada
  • Research Institute of McGill University Health Center, Glen site
    Montreal, Quebec H4A 3J1, Canada
  • Children's Hospital of Chongqing Medical University
    Chongqing, Chongqing 401122, China
  • Guangzhou Women and Children's Medical Center
    Guangzhou, Guangdong 510623, China
  • Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
    Wuhan, Hubei 430030, China
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan 410011, China
  • Children's Hospital of Soochow University
    Suzhou, Jiangsu 215003, China
  • Xi'an Children's Hospital
    Xi'an, Shaanxi 710003, China
  • Chengdu Women's and Children's Central Hospital
    Chengdu, Sichuan 610073, China
  • The Children's Hospital Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310057, China
  • Beijing Children's Hospital, Capital Medical University/Rheumatology Department
    Beijing, 100045, China
  • Hospital Metropolitano
    San Jose, 10103, Costa Rica
  • Universitaetsklinikum Erlangen
    Erlangen, Bayern 91054, Germany
  • St. Josef-Stift Sendenhorst
    Sendenhorst, 48324, Germany
  • Semmelweis Egyetem
    Budapest, 1094, Hungary
  • Nirmal Hospital Pvt Ltd
    Surat, Gujarat 395002, India
  • Sir Ganga Ram Hospital
    Rajinder Nagar, NEW Delhi 110060, India
  • Institute of Child Health
    Kolkata, WEST Bengal 700017, India
  • Institute of Post Graduate Medical Education and Research & SSKM Hospital
    Kolkata, WEST Bengal 700020, India
  • Rambam Health Care Campus
    Haifa, 3109601, Israel
  • Meir Medical Center - Pediatric Clinic
    Kfar Saba, 4428164, Israel
  • Istituto Giannina Gaslini Istituto Pediatrico di Ricovero e Cura a Carattere Scientifico
    Genova, Genoa 16147, Italy
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
    Milano, Milan 20122, Italy
  • Clínica de Investigacion en Reumatologia y Obesidad, S.C.
    Guadalajara, Jalisco 44650, Mexico
  • Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
    Monterrey, Nuevo LEON 64460, Mexico
  • Centro de Alta Especialidad en Reumatologia e Investigacion del Potosi, S.C.
    San Luis Potosi, 78213, Mexico
  • Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji im prof dr hab med Eleonory Reicher
    Warszawa, 02-637, Poland
  • Clinic of FSBEI HE BSMU MoH RF
    Ufa, Republic OF Bashkortostan 450083, Russian Federation
  • Federal State Budgetary Scientific Institution "Scientific and Research Rheumatology
    Moscow, 115522, Russian Federation
  • Enhancing Care Foundation
    Durban, Kwazulu-natal 4302, South Africa
  • Panorama Medical Centre
    Cape Town, Western CAPE 7500, South Africa
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • Hospital Universitario y Politecnico La Fe
    Valencia, 46026, Spain
  • Hacettepe University Medical Faculty
    Ankara, 06100, Turkey
  • Istanbul Goztepe Prof. Dr. Suleyman Yalcin City Hospital Department of Pediatric Rheumatology
    Kadikoy / Istanbul, 34722, Turkey
  • Communal Institution "Dnipropetrovsk Specialized Clinical Medical Center of Mother and Child n.a.
    Dnipro, 49006, Ukraine
  • Municipal non-Profit Enterprise
    Ivano-Frankivsk, 76014, Ukraine
  • CNE of Lviv Regional Council "Western Ukrainian Specialized Pediatric
    Lviv, 79035, Ukraine
  • Vinnytsia Regional Children's Clinical Hospital
    Vinnytsia, 21000, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in Mar 2024, 70 months.

Results were first posted in Jun 2025, 1 year 2 months after primary completion.

Of 36 phase 3 interventional studies under Arthritis, Juvenile, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 70. This study's 70 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2016
First posted
Dec 22, 2016
StartActual
May 10, 2018
Primary completionActual
Mar 27, 2024
CompletionActual
Mar 27, 2024
Results first posted
Jun 3, 2025
Last update
Jun 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03000439
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Dec 22, 2016
Start date
May 10, 2018
Primary completion
Mar 27, 2024
Completion
Mar 27, 2024
Results posted
Jun 3, 2025
Last update
Jun 3, 2025

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tofacitinib

Start the discussion